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 Osteoarthritis (OA) is the leading cause of disability in the US and is 
characterized by cartilage degradation, subchondral bone changes and synovial 
inflammation. OA presents a unique challenge as there are no approved disease 
modifying OA drugs (DMOADs) and the current mode of treatment is palliative therapy 
and eventual total joint replacement. Thus, there is a pressing, unmet clinical need to test 
and develop novel DMOADs to improve outcomes. This includes development and 
characterization of suitable animal models to provide a test-bed for screening 
therapeutics.  
 Cartilage is an avascular tissue containing water which makes imaging cartilage 
difficult. In order to study pre-clinical models of OA and test therapeutics, an efficient 
technique with quantitative outcome measures is required. Accordingly, the goal of this 
thesis was to investigate contrast based CT imaging (EPIC-µCT – Equilibrium 
partitioning of an ionic contrast agent)as a tool to test therapeutic strategies in a pre-
clinical rat OA model. First, we characterized two different models of joint degeneration, 
one induced by injection of monosodium iodoacetate (MIA) and a second, created 
surgically via medial meniscal transection (MMT). Our results indicated that the MIA 
model leads to global cartilage and bone degeneration whereas the MMT model produces 
focal defects, similar to human OA. Second, we tested the sensitivity of EPIC-µCT to 
detect effects of a broad spectrum matrix metalloproteinase inhibitor (MMPi) in the rat 
MMT model. Our results demonstrated that quantitative measures established by EPIC-
µCT were able to detect damage in cartilage and subchondral bone in response to MMPi 
treatment with greater sensitivity than the gold standard of histopathology. Finally, we 
 xx 
investigated the effects of micronized dehydrated human amnion/chorion membrane (µ-
dHACM) in the rat MMT model. Our results indicated a protective effect of a single 
intra-articular injection of µ-dHACM at 3 weeks. Treatment of an arthritic joint with a 
delayed injection also demonstrated a chondro-protective effect of µ-dHACM at a longer 
time point of 6 weeks. Denaturation of µ-dHACM led to loss of chondroprotective effect 
at 3 weeks.  
 Taken together, this thesis presents pioneering work on the use of EPIC-µCT as a 
quantitative technique to assess cartilage and also presents µ-dHACM as a novel 
DMOAD to be tested further. This work has provided new insights on the development 
of OA in the rat MMT model. It is also the first instance of using µ-dHACMas a 
therapeutic for OA which shows potential to be translated to large animal models and 
human clinical use. Going forward, EPIC-µCT can be used to screen other therapeutics 
efficiently and can be adapted to other diseasessuch as juvenile OA, rheumatoid arthritis 
and osteochondritis dissecans. Ultimately, this technique may enhance the drug testing 
phase for OA by enabling quicker screening, making the bench to clinic translation a 








Osteoarthritis (OA) affects nearly 27 million people in the US and represents the 
leading cause of chronic disability (Cutler and Ghosh 2012). It primarily manifests as 
joint degeneration, characterized in part by a decrease in proteoglycan (PG) content, 
fibrillation of the cartilage surface, reduction of articular cartilage thickness and 
subchondral bone sclerosis. Current treatment methods target pain relief for OA via non-
steroidal anti-inflammatory drugs (NSAIDs) since there are currently no clinically 
approved disease modifying OA drugs (DMOADs) demonstrating efficacy(Clouet, 
Vinatier et al. 2009). Despite multiple small animal model DMOAD experiments being 
conducted, the screening rate for drugs is severely limited by the lack of sensitivity of 
outcome measures and the time consuming process to achieve them. Equilibrium 
Partitioning of an Ionic Contrast agent via µCT (EPIC-µCT) is a recently developed 
technique that allows for evaluating articular cartilage changes with µCT(Palmer, 
Guldberg et al. 2006). It has been validated and was used to study joint degeneration 
induced by injecting a high dose of monosodium iodoacetate (MIA) into rat joints 
(Grogan, Miyaki et al. 2009). This MIA model, though commonly used, is not 
physiologically relevant to human OA. An alternative more relevant small animal model 
involves induction of OA via medial meniscal transection (MMT). However, the ability 
of EPIC-µCT imaging to analyze disease progression in the MMT model and detect the 
therapeutic efficacy of candidate DMOADs has not been previously evaluated.  
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DMOADs exist in various forms including broad spectrum agents that target 
inflammation and small molecule based therapeutics. Matrix metalloproteinase inhibitors 
(MMPis) are a class of small molecule based drugs which have previously shown 
efficacy when delivered systemically/orally in small animal models but have not yet been 
tested using EPIC-µCT (Clouet, Vinatier et al. 2009). Testing a drug that has previously 
been shown to have a therapeutic benefit will allow for assessing the sensitivity and 
applicability of EPIC-µCT as a tool to screen for DMOADs. Extracellular matrix (ECM) 
based materials are another class of therapeutics that are being tested for a variety of 
applications. Amniotic membrane, by virtue of its anti-inflammatory and anti-fibrotic 
qualities, may prove useful as an extracellular matrix based intervention for OA (Jin, 
Park et al. 2007, Diaz-Prado, Rendal-Vazquez et al. 2010). The objective of this proposal 
was to examine two distinct treatment strategies for OA in a rat joint degeneration model 
using EPIC-µCT. The central hypothesis of this work was that EPIC-µCT could be used 
to establish quantitative outcome measures which would be sensitive to detect effects of 
therapeutics in the rat OA model. We approached this objective through the following 
specific aims: 
 
Specific Aim I 
Utilize EPIC-µCT for localized 3D analysis of cartilage composition & morphology 
in rat joint degeneration models 
There is a need to develop faster, less destructive yet quantitative metrics to 
examine articular cartilage changes in preclinical OA models other than the current 
histological techniques. Our hypothesis was that EPIC-µCT could quantitatively detect 
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degenerative cartilage changes in the MIA and MMT model. To test this hypothesis, we 
utilized a low dose of MIA (0.3mg) injected intra-articularly or induced joint 
degeneration surgically in the MMT model. We defined localized regions of interest to 
facilitate detection of cartilage changes and compared the results to contralateral joints.  
We characterized the models by evaluating quantitative parameters such as cartilage 
thickness, volume, attenuation as well as measurement of focal defects via EPIC-µCT. 
Histology was performed to compare results with EPIC-µCT analyses. The outcomes of 
this aim are discussed in Chapter 3. 
Specific Aim II 
Examine sensitivity of EPIC-µCT analysis and quantify effects of broad spectrum 
MMP inhibitor in selected rat OA model 
Testing new therapeutics for OA in pre-clinical animal models requires a sensitive 
diagnostic tool to assess the effects of the selected therapeutic on the articular cartilage. 
Based on Aim 1, our hypothesis was that EPIC-µCT would be a more sensitive metric to 
characterize the rat MMT model compared to histopathology and could be used 
successfully to analyze effects of a MMPi in the rat MMT model at 3 weeks. Initially, 
EPIC-µCT was used to analyze the MMT model at 1, 2 and 3 weeks and the results 
compared with histopathology data. Next, an MMPi was orally delivered and tested in the 
rat OA model at 3 weeks. The joints were analyzed via both EPIC-µCT and 
histopathology. Additional analyses such as osteophyte characterization and subchondral 




Specific Aim III 
Quantify effects of micronized dehydrated human amnion/chorion membrane       
(µ-dHACM) on the progression of joint degradation in an established rat OA model  
A variety of DMOADs are currently being researched and tested. ECM based 
therapeutics have been shown to have improved wound healing outcomes. µ-dHACM is 
an ECM derived material which has been used for regenerative therapy applications such 
as corneal defects and tendon repair. However, its effects on articular cartilage 
degeneration have not been determined. Our hypothesis was that intra-articular delivery 
of micronized dHACM (EpiFix Injectable™) will ameliorate the progression and extent 
of joint degeneration in the rat MMT model and based on our results from Aim II, EPIC-
µCT would be able to assess changes in the articular cartilage in response to µ-dHACM. 
First, we tested the effects of dHACM in naïve rats followed by delivering it intra-
articularly in the OA model. Short-term effects were analyzed using EPIC-µCT at 3 
weeks. Longer term effects including treatment of a pre-arthritic joint via a delayed 
injection, were examined at 6 weeks. Denatured µ-dHACM was also tested both in vitro 
and in vivo. Outcome measures included EPIC-µCT analysis and histology.  The results 
of this aim are discussed in Chapter 5. 
Significance 
 The burden of joint diseases is enormous and is continually increasing, with only 
limited intervention options available. The incidence of OA is expected to rise with a 
growing ageing population as well as with an increase in the rate of obesity. The lack of 
effective DMOADs leads to only temporary pain relief options available to OA patients. 
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This leads to a loss of patient’s quality of life while creating an economic burden on the 
healthcare sector as well.  
 Development and testing of new therapies requires suitable animal models for OA 
combined with efficient diagnostic tools. There is considerable ongoing research 
exploring DMOADs and testing them in vitro and in pre-clinical animal models; 
however, the testing process in animal models remains inefficient and subjective. This 
makes the therapeutic testing process challenging, as extensive resources are required to 
screen potential DMOADs. Developing effective DMOADs and translating these to the 
clinic would require a suitable, well characterized pre-clinical model of OA with 
quantitative, objective outcome measures to use as a test-bed for evaluating potential 
DMOAD candidates. Accordingly, there exists a need to quantitatively characterize a rat 
OA model and assess the efficacy of this model using a suitable diagnostic tool to test 
therapeutics.   In this project, we used EPIC-µCT as a high throughput screening 
technique to test DMOADs in the widely accepted rat MMT model for OA. 
 
The work described in this thesis is significant because it presents innovative 
research on characterizing a well-accepted rat OA model using a quantitative contrast 
based imaging technique, followed by assessing the sensitivity of the technique and then 
utilizing it to test a novel tissue engineering based therapeutic strategy. No previous 
studies have demonstrated the use of EPIC-µCT as a tool to study disease modifying 
drugs for joint diseases. 3D quantitative analysis using EPIC-µCT provides a more 
complete picture of disease progression in the tissue as a whole with higher sensitivity of 
therapeutic efficacy than current 2D histopathology. EPIC-µCT is non-destructive 
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allowing for additional histology analysis on the same samples, which could additionally 
be beneficial as some outcomes, such as cellularity, cannot be observed with CT.  Overall 
this technique can provide a powerful tool moving forward for enabling higher 
throughput, fewer samples, and more sensitivity when screening new therapies for joint 
diseases.We have successfully established EPIC-µCT as a high throughput screening 
technique to test DMOADs in small animal models and evaluated the efficacy of two 
different therapeutics to slow the progression of joint degeneration. Additionally, this 
research has advanced our understanding of the progression of OA in the rat MMT model 
and presents results of an ECM based therapeutic as a potential DMOAD candidate. 
Ultimately, testing novel therapeutics in an efficient, quantitative manner will result in 
faster screening and improve the process of translating a new therapy through the pre-









 Articular cartilage is a smooth, white tissue which covers the ends of bones in 
various joints.    The joints themselves contain various components such as ligaments, 
supporting muscles and synovial membrane (Clouet, Vinatier et al. 2009). Hyaline 
articular cartilage is found on the ends of the bones in a joint where it provides a low 
friction surface allowing for joint movement (Athanasiou, Shah et al. 2001). 
Structure and Composition  
 Cartilage possesses a unique structure and composition that allows articulating 
surfaces to glide over each other with minimal friction (Forster and Fisher 1996). 
Additionally, cartilage assists in biomechanical activity of the joint by distributing forces 
and absorbing energy in combination with other tissues such as the meniscus in the knee 
joint (Ahmed and Burke 1983).  
 Cartilage is unique because it is avascular and has minimal innervation. This leads 
to minimal regenerative capacity of the tissue. A major component of cartilage tissue 
volume is composed of the ECM as opposed to chondrocytes. The ECM is mainly 
constituted of proteoglycans (PGs) and collagen (Huber, Trattnig et al. 2000, Hunziker 
2002). 




 Parts of this chapter have been adapted from Thote T, Moran S, Lin ASP, Willett NJ, Neu C, Guldberg 
RE. “Methods for Detection of Joint Degradation” in Morris P. (Editor), Biomedical Imaging: Applications 
and Advances. 2014 (In press). 
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 PGs are macromolecules with a basic PG unit consisting of a core protein with 
glycosaminoglycan (GAG) chains covalently bound to this core. The GAG chains are 
negatively charged which causes them to repel each other. This creates an osmotic 
imbalance that is partially balanced by influx of water into the tissue as well as due to 
cations in the surrounding area (Huber, Trattnig et al. 2000).  
 The major protein in cartilage is collagen. Collagen type II is most predominant 
though other types of collagen such as Type III, IX,X and XI have been identified in 
small amounts(Eyre, Weis et al. 2006). These different collagen types play different roles 
while creating the fibrillar structure of cartilage (Eyre 2004). Tightly packed collagen 
fibers allow for high tensile strength and dynamic compressive modulus of cartilage with 
collagen type II being predominant in its composition (Bader and Kempson 1994). 
 Articular cartilage is divided into three layers – superficial zone, transitional zone 
and deep zone (Fig 1). Collagen fibers are tightly packed in the superficial zone. These 
fibers display transition in their alignment in the transitional zone. In the deep zone, the 
collagen fibers are aligned perpendicular to the surface. The tidemark is the interface 
between the deep cartilage and the calcified cartilage. Below the calcified cartilage, lies 







Figure 1.Articular cartilage structure a) Zonal architecture of cartilage b) Safranin O 
micrograph of chondrocytes in the superficial zone. (Adapted from Grogan, Miyaki et 
al. 2009Creative Commons License doi:10.1186/ar2719 ) 
 
 During loading of the joint, the internal pressure on cartilage increases. The 
collagen fibrils prevent the cartilage from deforming under load. In the presence of 
persistent loading, an increase in pressure causes an outflux of water from the cartilage 
until equilibrium is reached. PG control the balance during static loading and loss of PGs 
leads to decreasing the compressive modulus of the tissue(Herzog and Federico 2006) . 
This same effect is observed when the collagen network is disrupted. Changes in 
mechanical properties of the cartilage affect the functional capacity of cartilage to 
withstand normal loading. Thus, alteration of biomechanical properties makes the 
cartilage susceptible to further injuries.  
Osteoarthritis 
 OA is a debilitating joint disease that causes damage to the cartilage and 




Pathophysiology & Etiology 
 OA is the leading cause of disability in the US and affects nearly 27 million 
people. The most prevalent joints affected are knee, hip, hand, foot and the spine with 
knee OA being the most common(Martel-Pelletier, Wildi et al. 2012).  
 The pathophysiology of OA is complex and involves changes at the molecular, 
cellular, and tissue levels. At the initial stage, OA is characterized by subchondral bone 
alterations, loss of cartilage thickness, and fibrillation of the surface layers, which leads 
to a loss of cartilage integrity (Clouet, Vinatier et al. 2009). During this stage, there is an 
upregulation of chondrocyte metabolism followed by eventual apoptosis of chondrocytes 
and a decrease in osteoblast activity that causes thinning of adjacent trabecular bone. PG 
and collagen synthesis is also increased at the initial stage of the disease. As the disease 
advances, there is a progressive loss of chondrocytes at all levels of cartilage with 
pronounced thinning of the cartilage matrix possibly leading to lesions and excessive 
bone remodeling where cartilage has degraded (Kim and Blanco 2007, Clouet, Vinatier et 
al. 2009). Greater stress on the collagen network may occur at this stage which exposes 
the cartilage to further damage, first in the transitional zone which may progress into the 
radial zone. As collagen and PG are integral for maintaining articular cartilage function, 
the mechanical properties of cartilage are also typically impaired at this stage(Aigner and 
Stove 2003).  
 Various enzymes that degrade articular cartilage and the surrounding ECM have 
been characterized. The levels of anabolic factors such as fibroblast growth factors 
(FGFs) and bone morphogenetic proteins (BMPs) have been shown to decline as OA 
progresses. Cytokines such as tumor necrosis factor (TNF) and interleukin-1(IL-1) have 
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been implicated in the increase in catabolic enzymes (Goldring and Goldring 2007). 
Matrix metalloproteinases (MMPs) are an important group of enzymes implicated in OA 
and often observed to be upregulated during OA progression. Other degrading enzymes, 
such as aggrecanases, have also been detected and their role in the development of OA is 
being studied (Burrage and Brinckerhoff 2007). 
 Advanced OA is associated with inflammation of the synovium, which leads to 
release of pro-inflammatory cytokines that cycle back and play a role in further cartilage 
degradation. Advanced OA is typically characterized by progressive erosion of the 
articular cartilage in combination with degradation of the subchondral bone(Loeser 
2004). There is some evidence suggesting that cartilage and bone changes are inter-
related in OA. Subchondral bone sclerosis and formation of osteophytes are typical 
features of OA. These factors affect cellular changes such as chondrocyte clustering in 
the earlier stages and increased chondrocyte apoptosis due to caspases in advanced 
OA(Loeser 2004). OA is therefore a multi-faceted disease affecting cartilage, synovium, 
and bone and involving interplay of multiple factors that create a negative cycle of 
progressive joint degeneration.  
 Secondary OA also exists in humans where cartilage changes occur as a 
consequence of a trauma or trigger which hampers the mechanical integrity of the tissue, 
usually by causing damage to the collagen network(Buckwalter and Brown 2004). 
Different causes of secondary OA have been identified such as high intensity impact joint 
loading, intra-articular fractures, ligament injuries and several metabolic disorders 
(Buckwalter and Martin 2006). 
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 Etiology of OA remains unclear to this day. Primary OA is correlated with 
increasing age but it is not necessarily considered as a normal ageing process(Crepaldi 
and Punzi 2003). Large scale follow-up studies in human populations have helped 
identify risk factors for primary OA(Buckwalter, Saltzman et al. 2004, Felson 2004, 
Cimmino and Parodi 2005). One, is the effect of gender with OA being more prevalent in 
women than men(Buckwalter and Lappin 2000). Another risk factor is high BMI or body 
weight(Schouten 1992). This factor combined with malalignment of joint puts the patient 
at high risk for OA(Sharma, Lou et al. 2000). Trauma to the knee not limited to accidents 
or sports injury(Gelber, Hochberg et al. 2000) particularly in the form of a 
meniscectomy(Roos, Lauren et al. 1998) also creates a high risk.  
OA is often observed to be clustered in families leading to a hypothesis that 
genetics may play a role as a risk factor as well(Cicuttini and Spector 1996). In a twin 
study, heritability of OA was estimated to range from 39-65%(Spector, Cicuttini et al. 
1996). However, OA is not caused by a single gene mutation. Multiple genetic loci for 
susceptible OA genes have been identified but these factors are not comprehensive 
(Aigner and Dudhia 2003, Peach, Carr et al. 2005). OA is a multifactorial complex 
disease that researchers continue to try and understand better. 
Prevalence 
 OA prevalence increases as people age. In the US, 27 million people suffer from 
clinical OA. OA is the most common form of arthritis. For population > 60 yrs., the 
prevalence rate of symptomatic knee OA is 10% in men and 13% in women. This number 
is expected to increase as the ageing population rises as well as the obesity epidemic 
(Zhang and Jordan 2010). 
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 Various studies have been performed to estimate the prevalence of OA. The age 
standardized prevalence of radiographic knee OA in adults age ≥ 45 was 19.2% among 
the participants in the Framingham Study and 27.8% in the Johnston County OA Project 
(Lawrence, Felson et al. 2008). In the third National Health and Nutrition Examination 
Survey (NHANES III), approximately 37% of participants age >60 years or older had 
radiographic knee OA (Lawrence, Felson et al. 2008). 
The table below shows the prevalence of OA for various joints as described by different 
studies.  
Table 1. Prevalence of OA  
 
 In addition to significantly affecting patients’ quality of life, OA also presents a 
large economic burden (Bitton 2009). In a study done in 1997, total medical expenditures 
for arthritis and other rheumatic conditions was $233.5 billion. By 2003, these costs 
Anatomic 
site 





Hip ≥45 Johnston County 
OA project (Jordan, 
Helmick et al. 2009) 
25.7 26.9 27.0 
Hand ≥26 Framingham OA 
study (Zhang, Niu et 
al. 2002) 
25.9 28.2 27.2 
Knee ≥26 Framingham OA 
study (Felson, 
Naimark et al. 1987) 
14.1 13.7 13.8 
All 
joints 
≥45 Framingham OA 
study (Felson, 
Naimark et al. 1987) 
18.6 19.3 19.2 
All 
joints 
≥60 NHANES III 
(Dillon, Rasch et al. 
2006) 
31.2 42.1 37.4 
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increased to #321.8billion (factoring in inflation) (Yelin, Murphy et al. 2007). A 
significant portion of these costs is attributed to OA and an estimate by Leigh et al, 
calculated the total annual costs of OA at 89.1 billion (Leigh, Seavey et al. 2001). While 
these are the direct costs of OA, there is also an indirect cost which includes lost wages, 
lost productivity and expenses from home care. A study based on claims database 
analysis calculated the indirect costs of OA at $4603 per person per year(White, 
Birnbaum et al. 2008).  
Treatment Strategies 
 Currently, there are no clinically approved disease modifying OA drugs 
(DMOADs) that have shown efficacy for OA. Current treatment methods are targeted 
towards reducing pain (symptomatic treatment) rather than trying to treat the underlying 
cause of the disease. Another issue with current symptomatic OA drugs are the side-
effect profiles which cause concerns particularly in chronic applications (Wieland, 
Michaelis et al. 2005). Researchers have suggested that treatment of OA should be 
tailored individually as there is a substantial discordance between radiographically 
diagnosed OA and knee pain. Depending on the patient, non-pharmacological treatments 
including exercises and weight reduction should also be discussed by the physician 
(Dieppe and Lohmander 2005) 
Pharmacological 
 The first line oral analgesic for knee OA is acetaminophen. It is widely 
recommended due to its favorable safety profile. In cases where patients do not respond 
to acetaminophen, the next line of treatment is non-steroidal anti-inflammatory drugs 
(NSAIDs).  The principal targets for NSAIDs are the isoforms of cyclooxygenase, COX1 
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and COX2. COX1 is constitutively expressed in many cell types, whereas COX2 is 
induced at the site of inflammation (Vane, Bakhle et al. 1998) . However, NSAIDs 
exhibit a risk of gastrointestinal side effects as the principle targets are also expressed in 
the kidney and other organs. Selective COX2 inhibitors were introduced in 1999, which 
provide equivalent efficacy while reducing the risk of GI complications(Warner, Giuliano 
et al. 1999). Recently, the cardiovascular safety of COX-2 selective and other NSAIDs is 
under scrutiny (Petit-Zeman 2004, Topol 2004).  Currently, COX-2 selective medications 
are contraindicated for people with ischemic heart disease and hypertension (Wieland, 
Michaelis et al. 2005). 
 Opioid analgesics are also useful alternatives in patients who cannot tolerate 
NSAIDs. Glucosamine and chondroitin products are also widely used for pain 
management in OA though their efficacy remains controversial (Wieland, Michaelis et al. 
2005).  
 Intra-articular injection of corticosteroids are also used to treat pain in OA. 
However, injections can only be given up to 4x/year as they are invasive and it is difficult 
to retain the drug in the joint space for a long time to achieve sustained efficacy (Gerwin, 
Hops et al. 2006). These therapies seem to provide temporary relief of pain in certain 
patients, but no convincing evidence for disease-modifying effects has been demonstrated 
(Ayral 2001). 
Disease Modifying OA Drugs 
 While no DMOADs have been currently approved, there are a few DMOADs in 
various phases of development. There a variety of compounds each with its own 
mechanism of action. Researchers suggest that initial degenerative changes are easier to 
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reverse and hence, early detection of OA is crucial. Using the knowledge about signaling 
pathways in chondrocytes and identifying various molecules that play a role in catabolic 
and anabolic processes, researchers are trying to develop DMOADs.  
 MMP-inhibitors have been tested which inhibit MMP gene expression for genes 
that have been implicated in OA (Burrage et al. 2007, Cawston et al. 2006, Murphy et al. 
2005). However, these MMPi's have had musculoskeletal side effects leading to failure in 
early clinical phase trials. Researchers are now trying to focus on selective MMPi's vs. 
broad spectrum inhibitors (Fingleton 2007). MMP-13 is one of the important MMPs 
expressed in OA cartilage and a MMP-13 inhibitor might be a viable target to pursue. In 
addition to MMPs, researchers have also tested IL-1b inhibitors. IL-1b is a pro-
inflammatory cytokine expressed in OA and an IL-1 inhibitor showed promise in small 
animal studies (Hunter 2011). However, this did not translate to humans as IL-1 receptor 
antagonist in various forms failed to meet its pain and structure endpoints (NIH 2008).  
 In addition to articular cartilage, subchondral bone turnover has also been 
implicated in OA. Hence, drugs originally targeted for osteoporosis are being proposed as 
candidates for OA treatment. Calcitonin, promotes inhibition of bone resorption.  A 
human clinical trial of salmon calcitonin (sCT) led to reduced levels of type II collagen 
and a pilot study exhibited decrease in pain scores (Karsdal, Byrjalsen et al. 2010). sCT is 
currently being tested in ongoing clinical trials to examine its effect on OA (NIH 2012) 
 Bone morphogenetic protein (BMP) has been used clinically in patients. BMP-7 is 
a member of the TGFβ superfamily and is known to have reparative effects on cartilage. 
Individuals with OA have decreased levels of BMP-7 and increased levels of 
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extracellular BMP antagonists (Hunter 2011). There is an ongoing clinical trial testing the 
efficacy of BMP-7 in knee OA (NIH 2010). 
 Growth factor changes have been implicated in OA as well. FGF-18 has been 
reported to have anabolic effects on the cartilage. It activates FGF receptor 2 and 
increases matrix formation while it inhibits cell proliferation. Preclinical studies showed 
potential of FGF-18 in a rat OA model (Moore, Bendele et al. 2005). Based on these 
studies, FGF-18 is currently the focus of an ongoing clinical trial (NIH 2010).  
 Apart from these, there are other agents in early stages of development (not in 
phase II trials). These include cathepsin K, proteoglycan 4 (lubricin), receptor activator of 
nuclear factor κB ligand (RANKL) and aggrecanase inhibitors (Hunter 2011). 
 One major obstacle is the difficulty in developing diagnostic methods for early 
cartilage degeneration, and subsequently for monitoring the effect of these novel 
pharmaceuticals (Goldring 2006, Qvist et al. 2008). In order to determine the efficacy of 
these novel medications, it is important to develop efficient methods that are capable of 
detecting the effects of each treatment in both pre-clinical and clinical stages.  
Surgical Treatments 
 Advanced OA might require surgical intervention if medical treatment does not 
sufficiently alleviate pain (Jordan et al. 2003). While knee replacement is the most 
common technique, other options are also available. 
 Arthroscopic procedures such as arthroscopic lavage and debridement have been 
used in patients who do not respond to pharmaceuticals (Frizziero et al. 2005, Segal et al. 
2006). High tibial osteotomy which involves surgical realignment of the loading axis of 
the limb has been used to treat medical compartment OA of the knee (Brouwer et al. 
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2005). In these procedures it is difficult to determine which patients will benefit the most 
and hence the results are still somewhat contradictory.  
 Joint replacement, while expensive, has been evaluated as being cost effective. It 
can alleviate pain and improve joint functionality as well. Timing of surgery is important 
to consider during joint replacement so that the patient gets the most benefit out of this 
procedure (Fortin, Penrod et al. 2002). The annual rate of total joint replacement is 
increasing with OA being the most common indication for total knee replacement (Katz 
2006).  
Cartilage repair techniques 
 Currently several cartilage repair techniques are in clinical use. These include 
osteochondral transplants, microfracture technique and autologous chondrocyte 
implantation (Chiang and Jiang 2009). These are targeted towards repairing articular 
cartilage lesions. These are limited in use for localized cartilage lesions, often of 
traumatic origin rather than treating primary OA (Chiang and Jiang 2009). 
 Development of efficient techniques and materials for cartilage repair is an 
important area of research. Biologic solutions based on tissue engineering techniques are 
also being explored as options (Nesic et al. 2006, Schurman et al. 2004).  
 
Small Animal models for OA 
 OA is a multi-factorial disease influenced by a variety of genetic and 
environmental factors. The need to understand the molecular events that occur in the joint 
in addition to having a platform for preclinical testing, has required researchers to 
develop suitable small animal OA models.  
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 Most models involve surgical insults in order to cause mechanical stress in the 
joint considering that injury is a common predisposing factor towards OA. Models have 
been developed in sheep (Cake et al., 2004), dogs (Mastberger et al., 2006), rabbits 
(Inouye et al., 1973), guinea pigs (Bendele et al., 1991), rats (Hayami et al., 2006; 
Laurent et al., 2006; Moore et al., 2005), and mice (Bendele, 2001).  Small animals in the 
form of rats and mice allow for relatively quick onset of the disease and are less 
expensive. 
Rat Models 
 Surgically induced destabilization of joints is the most widely used OA induction 
method. Most induction methods duplicate known injuries in humans such as anterior 
cruciate ligament transection (ACLT) and meniscal injury. ACLT or ACLT in 
combination with a partial medial meniscectomy has been used to induce OA in rats. It 
leads to PG loss, cartilage surface damage as well as subchondral bone sclerosis and 
osteophyte progression (Bendele 2002). The medial meniscal tear (MMT) model, is the 
most widely used model for inducing OA in rats(Gerwin, Bendele et al. 2010). It involves 
transection of the medial meniscus which leads to rapidly progressive cartilage 
degeneration indicated by chondrocyte & PG loss, fibrillation and osteophyte formation. 
Progressive changes occur and are detectable at 3 weeks and by 6 weeks tibial cartilage 
degeneration is focally severe with degeneration of surrounding matrix and prominent 
osteophytes (Moore, Bendele et al. 2005).  
 Apart from surgical destabilization, chemically induced joint degeneration has 
also been used to study effects of pain in rats. A common model for this is injection of 
monosodium iodoacetate. MIA is an inhibitor of glycolysis and induces chondrocyte 
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apoptosis and joint inflammation. Its utility as an OA injury model is debatable though it 
is validated as a suitable model for pain (Bendele 2002). Other agents that are used to 
induce cartilage degeneration include papain, collagenase and chondroitinase which 
degrade ECM components but may not be relevant to modeling human OA as the 
processes that precede and induce proteolysis in human OA do not occur (Little and 
Smith 2008). Additionally, the reagents may be quite different from the compounds that 
exist in human disease as well as in causing much higher degree of inflammation as 
compared to human OA.  
Murine Models 
 Murine models have been gaining popularity due to the homogeneity of genetics, 
ability to inbreed and option to create genetically modified strains. However, surgical 
induction in mice is difficult due to the small size of joints.  
 Microsurgical tools have been used to create mouse meniscectomy model that 
involved medial collateral ligament (MCL) transection coupled with medial 
meniscectomy. This leads to mild cartilage lesions on the medial plateau by 3-4 weeks 
(Clements et al., 2003).  
Spontaneous OA Models 
 Age-onset development of OA occurs in STR, DBA/1, and C57 Black mouse 
strains. These spontaneous models may help us understand the mechanisms beneath some 
human forms of OA (Yamamoto et al., 2005). The highest incidence of this type of OA 
occurs in the STR/1N strain (Jay, 1951) and the related STR/ort strain (Sokoloff and Jay, 
1956). In this model, cartilage lesions are detected histologically as early as 8 weeks of 
age and appear at the insertion of the medial collateral ligament and the medial tibial 
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plateau (Mason et al., 2001). Males have a higher incidence than females, and cartilage 
loss is most prevalent in the medial compartments of the knee joint. Interestingly, 
spontaneous obesity develops at three months of age in these mice, even when kept on a 
standard diet. Histological evaluation of knee joints from STR/ort strain using TUNEL 
assays showed an increasing number of apoptotic cells in cartilage covering medial 
tibialand femoral bone with advanced histological lesions (Mistry et al., 2004). This 
finding may be consistent with preceding biomechanical or metabolic stress on the 
cartilage (Mason et al., 2001). C57 Black mice are also susceptible to developing OA 
lesions in knee joints as a result of a genetic mutation with recessive Mendelian 
inheritance (Silberberg and Silberberg, 1960). Incidence and severity of OA based on 
histopathological cartilage damage increases with age in both males and females from 
20% at 2 months to 80% at 16 months (Yamamoto et al., 2005).One limitation with these 
models is the cost of experimentation as the animals need to be housed and maintained 
for up to a year for testing.  
Limitations 
 The pharmaceutical industry uses surgical models for pre-clinical studies 
extensively due to rapid, reproducible results. However, there are a few limitations to be 
considered. One, OA is not always caused by joint trauma and a lot of patients do not 
have a history of injury limiting our ability to translate data. Two, surgically induced OA 
models cause rapid damage whereas in humans OA takes several years to develop. Third, 
the surgery itself may be a confounding factor as it can damage other structures and start 
a wound healing cascade different from OA. Another important factor is that surgical 
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models lead to continued joint damage post-surgery which can limit the evaluation for 
therapies since the damage may be too aggressive (Little and Smith 2008).  
 With genetic models, the mice can be difficult to breed and maintain. It still isn’t 
clear what predisposes an individual animal to OA – is it the direct involvement of the 
gene or the developmental changes that occur downstream due to gene deletion. Another 
limitation with genetic models is that treatment interventions are difficult to test unless 
the gene abnormality occurs during adulthood/or upon induction of the disease.  
Imaging Techniques for Cartilage 
 Non-destructive imaging of cartilage to assess the composition and structure of 
articular cartilage remains an important need and there are a variety of techniques for this 
task. The spatial resolution necessary for assessing cartilage is usually the deciding factor 
in choosing what technique to use.  
 Traditional radiography and computed tomography (CT) techniques allow for 
evaluating changes in the bony matrix such as presence of osteophytes and joint space 
narrowing. Magnetic resonance imaging (MRI) allows for visualization of the cartilage. 
Within MRI, there are a variety of techniques to assess the cartilage such as 2D FSE, 3D 
FSE, 3D driven equilibrium Fourier transform etc. Each have their own strengths and 
limitations(Roemer, Crema et al. 2011).  3D MRI data can also be used for quantitative 
measurement of the cartilage. Trained users segment the bone and cartilage interface to 
isolate the cartilage area for evaluation. Contrast agents based MRI such as delayed 
gadolinium-enhanced MRI of cartilage (dGEMRIC) allows for accurate measurement of 
sGAG concentration in healthy and degrading joints (Winalski and Rajiah 2011).   
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 Recent research has also been exploring ultrasound as a method to analyze 
collagen structure in the cartilage. Sonography has demonstrated changes in the hyaline 
cartilage from early to late disease stages and in OA patients with synovitis, joint effusion 
with synovial thickening and proliferation can be observed by gray-scale ultrasound 
(Iagnocco 2010). Fourier transform infrared imaging spectroscopy (FT-IRIS) has also 
been shown to detect changes in sGAG content based on frequency absorbance spectrums 
(Rieppo, Hyttinen et al. 2009).  
Contrast based CT imaging  
 CT imaging was introduced in the early 1970’s and has since proven to be a 
valuable diagnostic tool (Holdsworth, 2002). Clinical CT imaging was targeted towards 
humans to generate two-dimensional images of internal structures; however, the 
resolution did not enable visualization for small animal models. With advances in 
technology, higher resolution images can be obtained, and today µCT systems are 
defined as systems which can perform volumetric CT analysis with an isotropic voxel 
spacing of < 100 µm. Clinical CT imaging does not have the resolution to verify OA 
progression. However, µCT is used to examine OA progression in small animal models 
by assessing cartilage using contrast agents and subchondral bone based on X-ray 
attenuation (Holdsworth, 2002).  
 The working principle for µCT imaging is based on generating contrast by X-ray 
attenuation.  As the X-ray beam penetrates a sample, it is attenuated based on the material 
properties of the object such as acquiring X-rays of fractured bone. An X-ray projection 
of the sample represents an image of the sum of local attenuations along the X-ray beam. 
To generate a 3D image, cameras capture X-ray attenuation data from many different 
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viewing angles. The collected data is run through image reconstruction algorithms, which 
produce 2D grayscale pixel matrices as slices of the object. After this step, the slices are 
processed and stacked to produce 3D images (Bartling S. H. , 2007). 
EPIC-μCT 
 Articular cartilage degradation is a primary characteristic of OA. Even though 
µCT provides an excellent option to visualize bone morphology, cartilage imaging and 
quantification is a challenge due to its low radiodensity. Traditionally, changes in 
cartilage have been evaluated by histology, which is time-consuming and destructive. 
Recent research has shown that specific contrast agents have the ability to increase 
contrast of cartilage to allow for measurements of morphology and composition of the 
tissue (Xie et al., 2009, Palmer et al., 2006, Silvast et al., 2009a). Within the cartilage 
extracellular matrix, negatively charged sulfated glycosaminoglycans (sGAGs) are 
attached to the PG backbone, and these allow for electrostatic interactions with contrast 
agents. sGAGs are of importance to researchers as a loss of sGAGs is an indicator of 
early OA cartilage destruction (Wakitani et al., 2007).  
 Hexabrix
TM
 320 (Covidien, Mansfield MA), a clinically available CT contrast 
agent containing ioxaglate (a negatively charged hexaiodinated dimer), was the first ionic 
agent used to increase cartilage radiopacity through EPIC-µCT. Specimens to be imaged 
using EPIC-µCT are first equilibrated in a solution containing an ionic contrast agent like 
Hexabrix
TM
 and then scanned with a µCT machine (Palmer et al., 2006).  Because of the 
Hexabrix
TM
 molecule’s negative charge, incubation of cartilage samples with Hexabrix
TM
 
yielded an equilibrium distribution of the agent that was inversely related to the density 
of the negatively charged sGAGs. The EPIC-µCT technique was shown to be effective in 
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visualizing cartilage in an in vitro degradation model whereas, for ex vivo proof of 
concept on an intact joint, a rabbit femur was imaged (Palmer et al., 2006). 
 EPIC-µCT has been validated with histological measurements of thickness and 
needle probe testing. A strong correlation between measurement of articular cartilage 
thickness with results from EPIC-µCT compared to both histology and needle probe 
testing was observed. The EPIC-µCT technique was also shown to be precise with a low 
coefficient of variation in measurement of cartilage volume, surface, and thickness. A 
follow up study in an ex vivo rat model determined 30 minutes as a suitable incubation 
time and 40% Hexabrix
TM
 as a suitable concentration to achieve desired contrast (Xie et 
al., 2009). In this study, sGAG optical density was compared to cartilage attenuation 
values and both were directly correlated. sGAG optical density decreased as cartilage 
attenuation increased with age. These studies establish EPIC-µCT as a viable technique 
to measure morphologic changes in cartilage over time (Xie et al., 2010, Xie et al., 2009). 
 Cartilage has recently been visualized in vivo using EPIC-µCT as well. The in 
vivo environment presents various challenges for examining cartilage. Some of the 
challenges include diffusion of contrast agent in vivo, injection of agent, retention of 
agent in the joint cavity as well as the ability to differentiate between cartilage and 
surrounding soft tissue and synovial fluid (Palmer et al., 2006). Piscaer et al. recently 
conducted a study that assessed cartilage degradation in an in vivo rat model (Piscaer et 
al., 2008). MIA, a chemical that causes chondrocyte death leading to cartilage 
degradation, was injected into rat knees. An equilibrium partition, though, was not 
reached in vivo due to diffusion from the joint cavity. However, a decrease in osmolarity 
and a higher concentration of Hexabrix
TM
usedin vivo enabled visualization of degraded 
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cartilage as early as 4 days in the MIA model (Piscaer et al., 2008).  At the end of 44 
days, there was a significant decrease in cartilage volume and increase in cartilage 
attenuation compared to the controls, indicating a loss of sGAGs and degradation of 
cartilage in the MIA models. Measuring contrast dye kinetics, Hexabrix
TM
 was shown to 
absorb more readily in the degraded MIA animal cartilage than normal cartilage.  
 Current imaging standards for EPIC-µCT of cartilage employ anionic contrast 




 II (Covidien Mansfield MA), a clinically 
available CT contrast agent containing iothalamate (a tri-iodinated monomer). While 
using these contrast agents is the current standard of practice, one limitation is their low 
sensitivity to changes in sGAGs, a major component of cartilaginous tissue. Negatively 
charged sGAGs repel anionic molecules, which results in limited diffusion of the imaging 
agents into cartilage. To address this issue, high concentrations of anionic contrast agents 
must be used to achieve linear correlations between X-ray attenuation and sGAGs 
(Bansal et al., 2010).  
 Recent research has also explored the use of cationic contrast agents for CT 
imaging. Cationic agents distribute into articular cartilage and generate a positive 
relationship with GAG content. Instead of an inverse distribution, cationic agents rely on 
electrostatic attraction to achieve a high concentration within the tissue. These agents 
have been tested using osteochondral plugs and future applications involve testing these 




EPIC-µCT AS A TOOL FOR LOCALIZED 3D ANALYSIS OF 





 Current histological scoring methods to evaluate efficacy of potential therapeutics 
for slowing or preventing joint degeneration are time-consuming and semi-quantitative in 
nature.  Hence, there is a need to develop and standardize quantitative outcome measures 
to define sensitive metrics for studying potential therapeutics. EPIC-µCT allows for 
quantitative analysis of articular cartilage in small animal models. We evaluated the 
hypothesis that EPIC-µCT can be used to quantitatively characterize morphological and 
compositional changes in the tibial articular cartilage in two distinct models of joint 
degeneration and define localized regions of interest to detect degenerative cartilage 
changes. First, we induced joint degeneration by injecting monosodium iodoacetate 
(MIA) or by performing medial meniscal transection (MMT) in rat. Three weeks post-
surgery, tibiae were analyzed using EPIC-μCT and histology. EPIC-µCT allowed for 
measurement of 3D morphological changes in cartilage thickness, volume and 
composition. Extensive cartilage degeneration was observed throughout the joint in the 
MIA model after 3 weeks. In contrast, the MMT model showed more localized 




 Portions of this chapter were adapted from Thote T, Lin AS, Moran SM, Guldberg RE, Willett NJ. 
Localized 3D analysis of cartilage composition and morphology in small animal models of joint 
degeneration. Osteoarthritis Cartilage 21(8): 1132-1141. License Number: 3370890841966 
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degeneration with regional thickening of the medial tibial plateau and a decrease in 
attenuation consistent with PG depletion.  Focal lesions were also observed and 3D 
volume calculated as an additional outcome metric. The MMT model showed similar 
features to human OA, including localized lesion formation and PG loss, while the MIA 
model displayed extensive cartilage degeneration throughout the joint. EPIC-µCT 
imaging provides a rapid and quantitative screening tool for preclinical evaluation of OA 
therapeutics.  
Introduction 
 OA affects 27 million people in the US (Lawrence, Felson et al. 2008). Current 
treatment methods are targeted towards pain relief for OA often in the form of non-
steroidal anti-inflammatory drugs (NSAIDs) (Felson, Lawrence et al. 2000). However, 
there are currently no clinically approved therapeutics that can halt the progression of OA 
by controlling cartilage erosion and chondrocyte loss (Abadie, Ethgen et al. 2004).  
 Developing disease modifying OA drugs (DMOADs) remains an unmet need for 
OA patients. Development of new imaging technologies is one of the requirements to 
better test potential therapeutics. Microcomputed tomography (µCT) has traditionally 
provided 3D, quantitative analysis of hard tissues. This imaging methodology has 
recently been modified to facilitate application to soft tissues, such as cartilage, using 
contrast agents. EPIC-µCT, allows for non-destructive evaluation of cartilage 
morphology and composition (Palmer, Guldberg et al. 2006). Previous studies have used 
different variations of µCT, such as EPIC-µCT and in vivo µCT arthrography to image 
cartilage in multiple joint degeneration models (Piscaer, van Osch et al. 2008; Piscaer, 
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Waarsing et al. 2008; Xie, Lin et al. 2009; Xie, Lin et al. 2010; Siebelt, Waarsing et al. 
2011; Kotwal, Li et al. 2012; Xie, Lin et al. 2012).  
 Several surgically and chemically induced models of OA have been developed in 
different species as platforms to evaluate disease pathology as well as to screen 
therapeutics (Oegema 1999; Bendele 2001). In this aim, two joint degeneration rat 
models commonly used to screen OA therapies were characterized—chemical induction 
of joint degeneration using monosodium iodoacetate (MIA) and surgical induction of 
joint degeneration via medial meniscus transection (MMT) (Bendele 2001; Bove, Flatters 
et al. 2009). Each method presents advantages for use in small animal models of joint 
degeneration. The MIA model is quick, easy, reproducible, and animals exhibit signs of 
OA related pain (Smith, Little et al. 1997). The MMT model is characterized by 
progressive cartilage degeneration involving chondrocyte and PG loss, osteophyte and 
lesion formation, collagen degradation and cartilage fibrillation (An and Friedman 1999; 
Janusz, Bendele et al. 2002; Little and Smith 2008; Gerwin, Bendele et al. 2010). A 
major difference in the two models is that the MIA model leads to global degenerative 
changes whereas the MMT model leads to more localized damage. The MIA model is 
also typically more aggressive and associated with increased joint pain. While a high 
dose MIA model—where PGs are nearly completely depleted—has previously been 
characterized using EPIC-µCT (Xie, Lin et al. 2012), EPIC-μCT has not been used to 
characterize a less aggressive low dose MIA model or the MMT model.  
 EPIC-µCT allows for high resolution 3D quantification of cartilage morphology 
and composition. It is a relatively high throughput technique, provides 3D volumetric 
data, and enables increased sensitivity and 3D visualization. The objectives of this study 
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were to use EPIC-µCT to quantitatively characterize morphological and compositional 
changes in the tibial articular cartilage in two distinct models of joint degeneration and 
define localized regions of interest to detect degenerative cartilage changes. We 
hypothesized that EPIC-µCT would be successful in detecting localized changes in 
articular cartilage and that the MIA model would show extensive cartilage degradation 
whereas the MMT model would have focal areas of damage.  
 
Materials and Methods 
Induction of Joint Degeneration 
 Georgia Institute of Technology Institutional Animal Care and Use Committee 
approved all experimental animal procedures (IACUC protocol #A09007). Two groups 
of rats were used in this study – 8-week old Wistar rats injected with MIA and weight 
matched Lewis rats (300-325g) that underwent MMT surgery (Janusz, Bendele et al. 
2002, Moore, Bendele et al. 2005, Xie, Lin et al. 2012).  
 Eight 8-week old male Wistar rats (Charles River, Wilmington, MA) were 
acclimated for one week. After anesthetizing with isoflurane, 0.3mg MIA (Sigma-
Aldrich, St. Louis, MO) in 50µl saline was injected into the joint space through the 
infrapatellar ligament of the left knee. Right knees were injected with 50µl saline as a 
contralateral control.  
 Seven weight matched adult male Lewis rats (Charles River, Wilmington, MA; 
300-325g) were acclimated for one week. The animals were anesthetized with isoflurane, 
and a small incision through the skin was made on the medial aspect of the left femoro-
tibial joint. The medial collateral ligament (MCL) was exposed by blunt dissection and 
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transected to visualize the joint space and medial meniscus.  The meniscus was transected 
completely at its narrowest point. The skin was closed with 4.0 silk sutures and then 
stapled using wound clips.  All surgical sites were observed daily for signs of abnormal 
healing. 
Assessment of Cartilage  
 Rats were euthanized via CO2 inhalation at 3 weeks after MIA injection or MMT 
surgery.  Tibiae were harvested, dissected free of surrounding tissues, and fixed in 10% 
neutral buffered formalin (NBF, EMD Chemicals, Gibbstown, NJ) for 3-4 days and then 
transferred to 70% ethanol (Palmer, Guldberg et al. 2006).  
 For EPIC-µCT, the proximal end of each tibia was immersed in 2ml of 30% 
Hexabrix 320 contrast agent (Covidien, Hazelwood, MO) and 70% ion-free PBS at 37ºC 
for 30 minutes, an incubation period known to result in equilibration of the agent 
(Palmer, Guldberg et al. 2006, Xie, Lin et al. 2009). Proximal tibiae were scanned using a 
µCT 40 (Scanco Medical, Brüttisellen, Switzerland) at 45kVp, 177µA, 200ms integration 
time, and a voxel size of 16µm(Xie, Lin et al. 2009).  
 Following scanning, tibiae were decalcified in Cal-Ex II (Fisher Scientific, 
Waltham, MA) for 14 days. Samples were routinely paraffin embedded. For comparison 
with EPIC-µCT images, sagittal sections were cut at 5µm thickness. Sections were 
stained for sGAGs with 0.5% Safranin-O and 0.2% Fast Green counterstain or 
hematoxylin& eosin. For each sample, three sagittal sections were used for thickness 
histomorphometry analysis and digital images of each section were captured. The 
cartilage thickness of each section was defined as the average value of 5 manual 
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thickness measurements at regular intervals perpendicular to the cartilage surface and the 
values for the three sections were then averaged. 
µCT regional analysis 
 Scanco evaluation software was used to assess 3D morphology and composition. 
Raw scan data were automatically reconstructed to 2D grayscale tomograms. These were 
rotated to sagittal sections, and the cartilage was contoured to separate it from trabecular 
bone and surrounding air (Palmer, Guldberg et al. 2006, Xie, Lin et al. 2012). The 
cartilage was segmented using a bandpass filter with a minimum threshold value of 175 
to eliminate air and 225 to eliminate bone from the raw image following which 3D 
images were generated. The threshold values were globally applied for both the left and 
right tibiae of all animals. 
 The MMT surgery produces localized cartilage degeneration on the medial 
plateau of the tibia. To observe localized effects of joint degeneration, we evaluated the 
medial tibial plateau in the MMT group. The regional analyses were replicated for the 
MIA tibiae for comparison. Four regional analyses were performed using different 
volumes of interest (VOI). For the MMT model, images were evaluated for: (1) Full 
articular cartilage in the proximal tibia including medial and lateral aspects (2) Medial 
plateau only (3) Medial 1/3 of the medial tibial plateau (4) Focal lesions on the medial 
plateau only (Fig 2). For the MIA model, only analyses (1) and (2) were performed for 
overall tibial articular cartilage and tibial medial articular cartilage respectively. Two 
outcome measures were defined for evaluation of focal defects: erosion (defect extended 
to less than 50% of cartilage thickness) and lesion (defect extended to more than 50% of 
cartilage thickness) (Pritzker and Aigner 2010).  To define VOIs of focal lesions, manual 
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contouring was performed in the isolated lesion area (typically ~8 slices). Within this 
VOI, segmented cartilage volume was subtracted from the total volume evaluated to 




 All data are presented as mean ± standard error of the mean (SEM). All data were 
expressed as mean ± standard deviation of the mean. The means of cartilage morphology 
variables—cartilage thickness, volume, and attenuation—fit a Gaussian distribution 
(Kolmogorov-Smirnov test) and were evaluated using paired t-tests to compare 
Figure 2.Representative image illustrating EPIC-µCT image analysis (tibial cartilage 
overlaid on bone) and volume of interest (VOI) designations. Pseudocolor coding 
(indicated at bottom) displays larger thicknesses in red and smaller thicknesses in blue B: 
Representative grayscale EPIC-µCT images of cartilage showing erosions (B) and lesion 
(C) (Inset shows zoomed in view). Lesion locations were identified by manually 
examining sagittal grayscale images slice by slice. 
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experimental and control tibiae for MMT and MIA groups separately. Each individual 
region (Overall cartilage, medial tibial plateau and medial 1/3 of medial tibial plateau) 
was evaluated independently with separate paired t-tests for each of the cartilage 
morphology variables listed above. All analysis was done using GraphPad Prism 
(GraphPad Software Inc. 5.01, La Jolla, CA). Statistical significance was set at a 95% 
confidence interval (p < 0.05). 
Results 
MIA Model Characterization 
MIA articular cartilage analysis 
 Representative images of tibial articular cartilage sections stained with Safranin-O 
in comparison with EPIC-µCT images are shown (Fig3). At three weeks post injection, 
the MIA cartilage displayed extensive PG loss which was not observed in the saline 
injected contralateral control (Fig 3). Images of sagittal sections from the medial tibial 
plateau of the tibia generated by EPIC-µCT for MIA samples are also shown (Fig 3). 
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Figure 3.Histology and EPIC-µCT images of tibial articular cartilage in the MIA model. 
A-C:   Representative saline contralateral control section, safranin-O  stained, 4X (A), 
corresponding EPIC-µCT thickness map from the same sample (B) and 10X safranin-O 
section (C). D-F:  Representative MIA injected sections, safranin-O stained, 4X (D), 
corresponding EPIC-µCT thickness map from the same sample (E) and 10X safranin-O 
section (F). 
 
Using the EPIC-µCT technique, the overall tibial cartilage was quantitatively 
evaluated for thickness, volume, and attenuation. At three weeks post injection, cartilage 
thickness in MIA tibiae decreased by 30%  compared to saline contralateral controls (Fig 
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4). Cartilage attenuation in MIA tibiae increased by 18% compared to saline contralateral 
controls (Fig4). 
 Following overall cartilage analysis, the medial tibial articular cartilage was 
evaluated separately. Average cartilage thickness and volume were 31% and 18% lower, 
respectively, compared to saline contralateral controls (Fig 4). Average attenuation was 
22% higher than saline contralateral controls (Fig 4). The decrease in cartilage volume 
was not observed when assessing the overall tibial plateau. 
 
Figure 4.Tibial articular cartilage variables quantified for MIA and saline contralateral 
control knees (paired comparisons). A-C: Overall tibial articular cartilage variables -  
Cartilage thickness (A); cartilage volume (B); cartilage attenuation (C). D-F: Medial 
tibial articular cartilage variables - Cartilage attenuation (D); cartilage thickness (E); 
cartilage volume (F). At 3 weeks post injection, overall and medial tibial cartilage 
thickness from MIA-injected joints was significantly lower than saline contralateral 
control cartilage. Overall and medial tibial cartilage attenuation from MIA-injected joints 
were significantly higher than saline contralateral controls. Medial tibial cartilage volume 
from MIA-injected joints was significantly lower than saline contralateral controls.  * = p 
< .05, n=8 
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MMT MODEL CHARACTERIZATION 
MMT tibial articular cartilage analysis 
 Representative images of tibial articular cartilage sections stained with Safranin-O 
in comparison with EPIC-µCT images are shown (Fig 5). The MMT cartilage displayed 
erosion on the histology image which was not observed on the contralateral control. The 
EPIC-µCT image of the MMT tibia also displayed both an erosion and a lesion on the 
sagittal section of the medial tibial plateau (Fig 5).  
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Figure 5.Histology and EPIC-µCT images of tibial articular cartilage in the MMT model 
3 weeks post injection. A-C:   Representative safranin-O stained control section, 4X (A), 
corresponding grayscale EPIC-μCT section (B) and 10X safranin-O section (C). D-F:  
Representative safranin-O stained MMT section, 4X (D), corresponding grayscale EPIC-
μCT section (E) and 10X safranin-O section (F). Green arrow in D & E indicate 




Cartilage histomorphometry measurements similarly showed a significant increase in the 
thickness of the medial tibial plateau in the MMT tibiae compared to the contralateral 
controls (Fig 6). 
 
  
Figure 6.Histology thickness measurements for medial tibial plateau. A-B: H&E stained 
sagittal sections of medial tibial plateau from contralateral control knee (A) and MMT knee 
(B). Insets show zoomed in region at 4x indicated by black box C: Histomorphometry 
measurements showing a significant increase in medial tibial cartilage thickness in MMT 
knees compared to contralateral control. Red lines on Fig A& B indicate thickness 
measurements. 5 measurements were taken per slice and each sample had 3 sagittal slices. 
Individual measurements from each slice were averaged and then measurements for all 3 





 Using the EPIC-µCT technique, the overall tibial cartilage was quantitatively 
evaluated for thickness, volume, and attenuation for the medial and lateral plateaus 
combined. The MMT joints did not show any difference in thickness (Fig 7).Average 
volume was significantly higher in the MMT tibiae (26.6%) compared to the contralateral 
controls (Fig 7). No significant difference in cartilage attenuation was observed when 
analyzing the overall tibial cartilage (Fig 7). 
The MMT medial tibial cartilage had significantly higher thickness and volume 
by 31% and 70% compared to contralateral controls (Fig 7).  In the analyses of cartilage 
in the full tibial plateau, cartilage attenuation was 25% higher in the MMT medial tibiae 
than contralateral controls (Fig 7). Though no change in average attenuation was 
observed for cartilage in the full tibial plateau, isolating the medial plateau resulted in 
detection of a significant difference in articular cartilage attenuation for MMT tibiae 
compared to controls. 
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Figure 7.Tibial articular cartilage variables quantified for MMT and contralateral control 
knees (paired comparisons). A-C: Overall tibial articular cartilage variables -  Cartilage 
thickness (A); cartilage volume (B); cartilage attenuation (C). D-F: Medial tibial articular 
cartilage variables - Cartilage attenuation (D); cartilage thickness (E); cartilage volume 
(F). At 3 weeks post-surgery, overall and medial cartilage volume from MMT joints was 
significantly higher than contralateral control cartilage. Medial tibial cartilage thickness 
and attenuation from MMT joints were significantly higher than contralateral controls. * 
= p < .05, n=7  
 
MMT Medial 1/3 of medial tibial articular cartilage analysis 
 Following analysis of the medial tibial plateau, further localized analysis was 
performed for the medial 1/3 of the medial tibial plateau. Evaluating this region, similar 
results were observed as with the whole medial plateau. Average cartilage thickness and 
volume in the MMT tibiae were 50%  and 90% higher, respectively, compared to 
contralateral controls; average cartilage attenuation was 35% higher compared to controls 
(Fig 8).  
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 The grayscale 2D images from the medial plateau of the MMT animals were 
viewed slice by slice to locate, visualize, and quantify focal defects. Pseudo-color 
attenuation maps were generated based on these images. Sagittal sections from the 
attenuation maps showed higher attenuation on the MMT tibiae near the lesion sites (Fig 
9). In addition to differences in attenuation, surface defects on the cartilage were also 
observed. Two MMT samples had three lesions and six MMT samples had one lesion 
each on the medial tibial articular cartilage. Six MMT samples had one erosion and one 
MMT sample had two erosions on the medial tibial articular cartilage. The average 
number of lesions was 1.57 ± .37 and average number of erosions was 1.14 ± .14 for the 
MMT tibiae, and no defects were observed on the controls. The average lesion volume 
was 0.00393 ± .003 mm3 for MMT tibiae, and no lesions were found on any of the 
contralateral controls (Fig 9).   
Figure 8.Medial 1/3 tibial articular cartilage variables quantified for MMT and 
contralateral control knees (paired comparisons).  A: Cartilage thickness; B: cartilage 
volume; C: cartilage attenuation. Cartilage thickness and volume from MMT surgery 
tibiae were significantly higher than contralateral control cartilage. Average cartilage 
attenuation in MMT surgery tibiae was significantly higher than the respective 






The average focal lesion volume was only 7.2% of the average medial 1/3 medial 
cartilage volume and 2.1% of the average medial plateau cartilage volume. The average 
focal lesion volume accounted for only .13% of the full cartilage volume when medial 
and lateral plateaus were combined. Because lesion volumes represented such a small 
region in proportion to the full cartilage volume, localized assessment clearly enhanced 
detection of morphometric differences between MMT and controls. 
Figure 9.Representative sagittal attenuation maps of medial tibial plateau for control (A) 
and MMT (B) (Inset shows zoomed in view). Red displays higher attenuation levels and 
green indicates lower attenuation. Red arrow indicates lesion site in MMT. Higher levels 
of attenuation were seen surrounding the lesion site for MMT tibiae. C: Focal lesion 




 The study of animal models of joint degeneration is essential for evaluating 
potential therapeutics and understanding the pathogenesis of cartilage loss. Studying the 
progression of OA in humans is challenging because of poor evaluative tools and limited 
access to diseased tissue during early development and through disease progression. 
Suitable animal models for research are consistent, reproducible, have an appropriate 
time frame of progression for high-throughput screening and recapitulate human 
pathology (Little and Smith 2008). Cartilage degeneration has been previously 
demonstrated in the two most widely used methods of joint degeneration in small 
animals—the  MMT model (Bendele 2001, Janusz, Bendele et al. 2002, Moore, Bendele 
et al. 2005, Wancket, Baragi et al. 2005, Bove, Laemont et al. 2006) and the MIA model 
(Kalbhen 1987, Guingamp, Gegout-Pottie et al. 1997, Fernihough, Gentry et al. 2004, 
Wancket, Baragi et al. 2005). Histopathology was the primary analytical method for these 
previous studies. EPIC-µCT allows for efficient, non-destructive 3D imaging and 
localized analysis, providing quantitative methods to assess cartilage thickness, 
attenuation and volume among other variables. For this study, the MIA and MMT models 
were quantitatively characterized via EPIC-CT to measure localized variables of 
attenuation, thickness and volume.  
 The results from the current low dose MIA study indicated an overall thinning of 
the cartilage layer. These are consistent with a previous dose response study for MIA 
which showed that 0.3mg was the lowest dose that caused articular cartilage damage 
covering the entire articular surface (Guingamp, Gegout-Pottie et al. 1997). In another 
study, Safranin-O staining indicated hypertrophied and disorganized chondrocytes as well 
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as degeneration of the cartilage surface at 3 weeks at the 0.3mg dose and more extensive 
damage at a 3mg dose (Kobayashi, Imaizumi et al. 2003). It is to be noted that these 
previous studies did not assess global and regional degeneration of the cartilage nor did 
they use quantitative techniques. In the current study, attenuation was significantly 
increased in the MIA joints, which was indicative of decreased PG content. Similarly, the 
Safranin-O staining showed severely depleted sGAGs. In regional analyses and the 
overall tibial plateau, the low-dose MIA model showed reduced cartilage thickness, 
volume as well as increased attenuation.  
 The MIA model remains the current standard to assess pain therapeutics asit is 
easy to use and is reproducible. Hence, some studies have tested DMOADs and NSAIDs 
in this model due to its widespread prevalence (Smith, Little et al. 1997, Bove, Calcaterra 
et al. 2003, Combe, Bramwell et al. 2004, Bar-Yehuda, Rath-Wolfson et al. 2009, 
Fitzpatrick, Green et al. 2011).  Our results showed uniform thinning and PG loss even in 
this low dose MIA model. This is not a typical presentation of human OA and does not 
correspond with many of the OARSI recommended OA histopathology grading 
features(Gerwin, Bendele et al. 2010). The MIA model represents biochemically induced 
OA and disease progression is expedited in the low dose model. This can be an issue 
regarding the suitability of this model to test disease modifying therapeutics for knee OA. 
Additionally, transcriptional profiling of gene expression has shown little overlap with 
this model and human OA and the disease process induced by MIA causes rapid cartilage 
and subchondral bone damage (at < 3 weeks). This extensive damage suggests that the 
time-frame of disease progression is much faster in the MIA model than OA progression 
in humans (Guingamp, Gegout-Pottie et al. 1997, Combe, Bramwell et al. 2004, Barve, 
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Minnerly et al. 2007). Thus, the MIA model shows different genetic, compositional and 
morphological changes than normally observed in human OA. Despite this, the MIA 
model does have an advantage in detecting joint pain-related behaviors due to the rapid 
damage caused to the articular cartilage (Little and Smith 2008). It remains the more 
popular model for testing therapeutics targeted towards OA symptoms but has limited 
utility for testing DMOADs. 
 In the MMT model, overall and regional changes in cartilage parameters were 
detected. While changes were detectable at the overall level, most were in the medial 1/3 
region. This observation that cartilage damage was most extensive in the outer 1/3 was 
similar to previous reports in the rat MMT model and attributed to the fact that this is the 
load bearing region that is destabilized (Bendele, McComb et al. 1999, Janusz, Bendele et 
al. 2002, Moore, Bendele et al. 2005). Though the medial 1/3 of the medial tibial plateau 
displayed cartilage thickening in the MMT model, focal lesions were also observed. A 
previous study supported the identification of localized lesions in the MMT model 
through immunostaining for type II collagen neoepitope antigen (TIINE) antibody 
(Wancket, Baragi et al. 2005). These lesions had not been previously quantified. Results 
from the present study showed that the lesion volume accounted for a small percentage 
(2.1%) of the medial plateau cartilage volume. The lesions compared to the full tibial 
articular cartilage layer occupied an even smaller fraction of the total volume, making 
cartilage changes challenging to detect when performing an overall cartilage analysis. 
 The increase in thickness for the medial plateau contradicts studies that have 
shown cartilage thickness to be reduced in MMT rats at 3 weeks (Janusz, Bendele et al. 
2002, Moore, Bendele et al. 2005).  To confirm this thickness increase that was measured 
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via EPIC-µCT, histomorphometric measurements were made and similarly showed a 
significant increase in cartilage thickness in the medial tibial plateau of the MMT animals 
compared to contralateral controls. Other studies have also reported thickening of OA 
cartilage in humans, beagles and rabbits (Muir H 1987, Arokoski, Jurvelin et al. 2000, 
Calvo, Palacios et al. 2001, Oeppen, Connolly et al. 2004, Cotofana, Buck et al. 2012). 
Another study in dogs, reported a transient episode of chondrocyte proliferation and 
increased matrix production within the lesion site and superficial zone of the adjacent 
articular cartilage in response to destabilization of joints (Pinals 1996).  
 In addition to thickening of cartilage, another factor contributing to the increase in 
thickness/volume could be cartilage-like structures called chondrophytes. Thickening of 
marginal zone cartilage and generation of chondrophytes and osteophytes has also been 
reported as a result of destabilization of the joint or injury in many animal models 
including the MMT model at 3 weeks (Pinals 1996, Bendele 2001, Bove, Laemont et al. 
2006, Blaney Davidson, Vitters et al. 2007, Wei, Kulkarni et al. 2010). A previous study 
hypothesized that the observed peripheral thickening could be an adaptive or 
compensatory mechanism to increase articular cartilage surface though no data was 
presented on PG content (Arokoski, Jurvelin et al. 2000). The cartilage volume from the 
MMT tibiae in the medial 1/3 region increased by 90% compared to the control tibiae. 
Formation of these chondrophyte/osteophyte structures could augment measured cartilage 
volume and thickness because diffusion of contrast agent into the chondrophyte would be 
expected to be similar to that of articular cartilage. Even though we observed higher 
volume and thickness, the average attenuation remained higher for the MMT tibiae 
indicating lower cartilage quality and depleted PG content.  
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OA is a multifactorial disease and there are several contributing factors to disease 
progression. Focal lesions on the articular cartilage have been observed in humans with 
early stage OA, and are considered to be among factors involved in OA progression 
(Clouet, Vinatier et al. 2009). The MMT model displayed focal lesions when regional 
analysis was performed using EPIC-CT. While histology can identify lesions, the 2D 
nature of the technique means that lesion incidence and overall volumes cannot be 
quantified.  EPIC-µCT allowed for both slice-by-slice visualization and volumetric 
quantification of these lesions. Our ability to further discern the sensitivity of the  EPIC-
µCT  technique to measure more subtle PG changes was limited by the fact that sham 
surgery was not performed. Contralateral control limbs were used as negative controls as 
sham surgeries do not develop lesions (Allen, Mata et al. 2012), and this additionally 
allowed us to minimize animal numbers. The MMT model displayed several 
characteristics similar to OA characteristics in humans such as peripheral thickening, loss 
of PGs, erosion of cartilage and localized lesions.  
 Though the objectives of this study were not to directly compare MIA and MMT 
models, some interesting overall observations exist.  The data show widespread cartilage 
degeneration in the low dose MIA model and localized degradation in the MMT model. 
The MIA model appears to cause greater damage in full tibial plateau cartilage compared 
to controls; whereas, this difference at the full tibial plateau level was not detected in the 
MMT model at 3 weeks. It should be noted that two different strains of rats were used in 
this study. Based on previous studies, the standard rat strain for the MIA model is Wistar 
and for the MMT model is Lewis (Gerwin, Bendele et al. 2010). Direct comparison of 
absolute quantitative values are not appropriate and thus, not performed. Although there 
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may be variations in the response of different strains to the two methods used to induce 
joint degeneration, this limitation does not alter the conclusions of the study. Another 
limitation of our analysis was that all measurements were performed in the sagittal plane 
as established previously in the EPIC-μCT protocol, and this limited our ability to 




SENSITIVITY OF EPIC-μCT ANALYSIS TO QUANTIFY EFFECTS 
OF BROAD SPECTRUM MMP INHIBITOR IN RAT MEDIAL 
MENISCAL TEAR MODEL 
Abstract 
 Cartilage degeneration is the signature pathology feature of degenerative joint 
diseases, which are the most common cause of pain and disability in the United States. 
The development of effective therapies for cartilage protection has been limited by a lack 
of efficient quantitative cartilage imaging modalities in preclinical in vivo models. EPIC-
μCT can quantitatively analyze articular cartilage and has been used to characterize the 
rat MMT model. The application of this technique to test therapeutic efficacy of a disease 
modifying OA drug (DMOAD) has not yet been tested. Also, the technique while used to 
characterize the MMT model has not been validated via a direct comparison to histology. 
The objective of this study was two-fold: first, to validate EPIC-μCT in the rat MMT 
model; and second, to quantitatively assess the sensitivity of EPIC-μCT to detect the 
effects of matrix metalloproteinase inhibitor (MMPi) therapy on cartilage degeneration. 
EPIC-µCT was shown to provide simultaneous 3D quantification of multiple parameters 
of joint health, including cartilage degeneration and osteophyte formation. In MMT 
animals treated with MMPi, OA progression was diminished, as measured by 3D 
parameters such as lesion volume and osteophyte size. A post-hoc power analysis showed 
that EPIC-μCT was significantly more sensitive than histopathology requiring 
approximately 50% fewer animals to detect a therapeutic effect of MMPi. This is the first 
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study to demonstrate that EPIC-μCT has higher sensitivity than composite histopathology 
scoring and that 3D imaging provides more information to distinguish the specific effects 
of a therapy on cartilage. EPIC-μCT is a powerful tool that will provide robust, 
reproducible and quick methodology to identify new cartilage protective drugs in the pre-
clinical development stage. 
Introduction 
 OA is characterized by the progressive loss of normal structure and function of 
articular cartilage(Loeser, Goldring et al. 2012). OA affects the entire joint including the 
subchondral bone, the synovium andperiarticular tissues (Loeser, Goldring et al. 2012). 
People with OA and cartilage injury can experience severe pain and limited motion. 
Currently there are no FDA approved drugs that can modify cartilage degeneration, 
resulting in the need for improved therapeutics. 
Development of new therapeutics requires multiple steps starting with in vitro 
screening, small animal testing, large animal testing and eventually clinical trials. 
Substantial progress has been made in recent years to improve throughput, decrease costs, 
and provide better data with predictive indicators of the potential efficacy of a drug in 
humans. Much of this progress has been at the in vitro screening stage with techniques 
that include microarrays, microfluidics, and multiplex systems; however, the in vivo 
stages for screening of joint therapeutics remain slow, expensive, and with few 
quantitative outcomes. 
In order to screen prospective therapeutics, the MMT model in the rat is becoming 
the accepted standard as the primary in vivo screening model. The model displays 
similarities with pathologies observed in human OA such as PG loss, erosion/lesion 
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formation, osteophytes and subchondral bone sclerosis (Gerwin, Bendele et al. 2010). A 
number of pharmaceutical companies have recently used this model to screen potential 
therapeutics including Pfizer, Lilly Research Corp, Wyeth and Abbott Laboratories 
(Bove, Laemont et al. 2006, Baragi, Becher et al. 2009, Flannery, Zollner et al. 2009, 
Mapp, Walsh et al. 2010, Wei, Kulkarni et al. 2010). Most of these studies use 
histological analysis with semi-quantitative pathological scoring for assessing therapeutic 
efficacy as it is the current gold standard. A major limitation of this technique couple 
with the rat MMT model is that it requires at least three weeks of treatment to 
demonstrate efficacy of potential therapeutics with a minimum of 20 animals per group 
(Gerwin, Bendele et al. 2010). The testing of drugs in an efficient and less expensive 
manner is limited by the high animal number requirement and long dosing period. 
The development of 3D high resolution imaging techniques that provide 
quantitative structural and compositional analyses in addition to traditional histological 
assessment has become a milestone that has expedited the development of novel 
therapeutics in some fields. In the musculoskeletal field, this approach is true for μCT 
analysis of hard tissues, such as analyzing the efficacy of osteoporosis therapies for bone 
(Borah, Dufresne et al. 2004, Kleerekoper 2006, O'Neal, Diab et al. 2010, Kawai, 
Modder et al. 2011). The ability to quantify 3D changes in bone microarchitecture 
provided substantial new insight into the mechanism of disease progression and 
accelerated the development of effective therapies for osteoporosis which are now 
clinically available (Borah, Dufresne et al. 2004, Kleerekoper 2006, O'Neal, Diab et al. 
2010, Kawai, Modder et al. 2011). Similar 3D analysis of soft tissues has been limited; 
however, in recent years, there has been progress using contrast enhanced imaging 
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techniques for soft tissues. These are often based on equilibration of an ionic contrast 
agent into the soft tissue and then correlating the attenuation of the contrast agent to 
structural and biological parameters. As described earlier, EPIC-µCT allows for 
quantitative imaging of cartilage (Palmer, Guldberg et al. 2006). Using this technique we 
have shown that we can measure structural and compositional parameters of cartilage 
including PG loss, incidence of lesions and erosions, and volume of lesions; our next 
objective was to use this technique to evaluate the efficacy of a disease modifying 
therapy in a preclinical model of OA (Thote, Lin et al. 2013).  
The aim of this study were two-fold: first, to perform a direct comparison of 
EPIC-μCT analysis to histopathological scoring looking at the development of OA in the 
rat MMT model; and then, to use EPIC-μCT to quantitatively assess the efficacy of a 
therapy for OA, in this case an MMPi, and similarly perform a direct comparison to the 
gold standard of histopathology. Our hypothesis was that EPIC-μCT would provide a 
more sensitive analytical method than histopathology requiring fewer samples and 
allowing for the quantitative analysis of more parameters.  
Materials and Methods 
Induction of Joint Degeneration 
 All animal studies were conducted at Abbvie Laboratories in accordance with 
Institutional Animal Care and Use Committee (IACUC) guidelines and the National 
Institutes of Health Guide for Care and Use of Laboratory Animals. Abbvie Laboratories 
facilities are accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). 
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Weight matched Lewis rats (300-325g) were subjected to MMT surgery based on 
previously established studies (Janusz, Bendele et al. 2002, Moore, Bendele et al. 2005, 
Xie, Lin et al. 2012). Two separate studies were performed. In the first study animals 
were separated into two groups: sham surgery or MMT surgery.  The sham surgery was 
performed by exposing the joint and transecting the medial collateral ligament. In MMT 
animals the exposed meniscus was then transected at its narrowest point. The joint and 
skin were then closed with sutures.  Animals were euthanized at 7, 14, or 21 days (at each 
of the time points, n=5-6 for MMT and n=3 for sham animals). In the second study 
animals were separated into three groups: Sham surgery (n=15), MMT +MMPi (n = 19) 
and MMT+vehicle (n=21). The MMPi used in this study (biaryl ether retro-hydroxamate) 
is a broad-spectrum, matrix metalloproteinase (MMP) inhibitor (Upadhyay, Baker et al. 
2013). Rats were administered the MMPi drug (30mg/kg) orally 2x/day for 21 days post- 
surgery.    
Histopathology Scoring 
The scoring of the joints was done using parameters from the scoring scheme 
described by Gerwin et al. (Gerwin, Bendele et al. 2010). Sections were analyzed 
microscopically and scored by a trained pathologist. For each knee, three sections were 
scored and then the average of the scores was used. Parameters that were scored include: 
cartilage degeneration for each zone (3 zones), a 3 zone sum of cartilage degeneration, 
subchondral bone, and osteophytes. Osteophyte width, width of the marginal zone, and 
cartilage degeneration width (performed in the MMPi study only) were measured 
separately by ocular micrometers. Detailed descriptions of the different scoring 
parameters were previously published (Gerwin, Bendele et al. 2010). 
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µCT regional analysis 
The MMT surgery involved an injury to the medial side of the knee joint through 
transection of the medial meniscus. As a result, the medial plateau of the tibia was more 
susceptible to injury. To observe localized effects of joint degeneration, we evaluated the 
medial tibial plateau in all groups. (Gerwin, Bendele et al. 2010). 
Scanco evaluation software was used to assess 3D morphology and composition. 
Raw data were automatically reconstructed to 2D grayscale tomograms. These were 
rotated to sagittal sections, and the cartilage was contoured to separate it from trabecular 
bone and surrounding air (Palmer, Guldberg et al. 2006, Xie, Lin et al. 2012). The 
cartilage was segmented using a threshold value of 175-225 and then 3D images were 
generated. Four regional analyses were performed using different volumes of interest 
(VOI). For the MMT model, images were evaluated for:  (1) Medial plateau only (2) 
Medial 1/3 of the medial tibial plateau (3) Focal lesions on the medial plateau only (Fig 
10). Two outcome measures were defined for evaluation of focal defects: erosion (defect 
extended to less than 50% of cartilage thickness) and lesion (defect extended to more 
than 50% of cartilage thickness) (Pritzker and Aigner 2010).  To define VOIs of focal 
lesions, manual contouring was performed in the isolated lesion area (typically ≈ 8 slices) 
to simulate the curvature of the surrounding cartilage surface excluding the subchondral 
bone and surrounding air. Within this VOI, segmented cartilage volume was subtracted 
from the total volume evaluated to compute lesion volume.  
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Analysis of the osteophytes was performed after the 2D grayscale tomograms 
were rotated to coronal sections (Fig 11). The medial marginal area was contoured for 
osteophyte growth. The marginal osteophyte was segmented using two different 
threshold values: 1) 130-1000 to include both mineralized matrix and cartilage, 2) 265-
1000 to include only the mineralized matrix. Outcome measures defined for marginal 
osteophytes included total osteophyte volume, total osteophyte thickness, mineralized 
osteophyte volume and cartilaginous osteophyte volume.  
 
Figure 11.Representative images illustrating osteophytes in coronal tibial section      
No osteophyte (OP) in sham joint (A), outline of osteophyte in MMT joint (B), total 
osteophyte (indicated in white) in MMT joint (C) and mineralized matrix (indicated in 
white) in MMT joint (D) 
 
Figure 10.Representative CT images indicating articular cartilage volume of 
interest and cartilage degeneration. A: Rat tibial articular cartilage overlay on bone 
indicating volumes of interest. B: Representative image illustrating erosions 




Statistical analysis   
All data were expressed as mean ± standard error. Cartilage morphology 
parameters were evaluated using ANOVA with a Tukey test to compare between selected 
groups using GraphPad Prism Software (GraphPad Prism Software Inc. 5.01, La Jolla, 
CA). Statistical significance was set at a 95% confidence interval (p < 0.05). 
Power analysis was performed by selecting a desired power of 0.8. Effect size 
was calculated for unequal sample sizes based on t-test data between the MMPi treated 
and vehicle treated group. These data were used to calculate the total sample size using 
G*Power (G*Power Version 3.1.3, Universitat Kiel, Germany). 
 
Results 
MMT Time-point Study 
The rat MMT model was analyzed using both EPIC-μCT and histopathology. 
These results were directly compared for the same set of samples. Representative coronal 
sections from histology and EPIC-μCT display qualitatively similar results in disease 
progression over three weeks (Fig 12). Osteophytes, erosions and PG loss can be 
observed in the comparable EPIC-μCT and histology sections.  
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 Histology sections were scored by a histopathologist based on the scheme 
described by Gerwin et al (Table 2). The results include tibial 3-zone sum score, total 
cartilage degeneration score, the osteophyte width, and the total joint score (Gerwin, 




Figure 12.Representative histology and EPIC-μCT images depicting OA progression 
over 3 weeks. A – D: Toluidine blue stained MMT joints showing no damage in 
sham (A), cartilage surface erosion at week 1 in MMT joint (B), increased cartilage 
surface erosion at week 2 in MMT joint (C) and development of osteophyte (red 
arrow) and severe cartilage erosion at week 3 in MMT joint (D). E-H: Corresponding 
EPIC-μCT images for the samples as sectioned via histology indicating progression 
of cartilage degradation. No damage observed in sham (E) or week 1 MMT joint (B). 
Increased areas of attenuation observed in MMT joints at week 2 (G) and 3 (H) as 
indicated by black arrow. Red arrow indicates area of mineralization within marginal 
osteophyte at week 2 and week 3 in MMT joints. Red indicates higher attenuation 





 Progression of the MMT model from week 1 to week 3 was analyzed. At week 1, 
the 3 zone sum score was significantly higher in the MMT animals compared to sham. 
This increase was consistent up to week 3 though no significant difference between these 
values at week 1 and week 3 were observed (Fig 13). EPIC-μCT data showed a 
significant increase in cartilage attenuation at week 2 in MMT animals, but no difference 
was observed at week 1. Lesion volume significantly increased between 2 and 3 weeks 
post-surgery in MMT treated animals (Fig 13). 
Table 2.Histology data for joint parameters for sham and MMT animals at weeks 1, 2 






Additional parameters, including cartilage thickness, volume and lesion and erosion 
incidence, were measured by EPIC-μCT. Lesion incidence was significant at week 3 and 
erosions were significant as early as week 2 (Table 3). 
Figure 13.Quantification of cartilage degeneration in MMT joints over 3 weeks. A. 
Histo-pathological 3 zone sum score is significantly increased in MMT joints at 
weeks 1, 2 and 3 compared to shams B. Cartilage attenuation is significantly 
increased in MMT joints at weeks 2 & 3 compared to shams. C. Cartilage lesion 
volume is significantly increased in MMT joints at week 3 compared to shams, and 
MMT joints at week 1 & 2. n = 5-6/group for CT data; n= 3 for sham and n = 5-6 
for MMT for histology data. 
* = p < 0.05, sham significantly different from MMT (One way ANOVA with 




Osteophytes were observed in the MMT animals on the medial tibial plateau via 
both EPIC-μCT and histopathology. The marginal tissue thickness was significantly 
higher in the MMT animals compared to sham animals at week 2 (above the 200 μm cut 
off for classification of an osteophyte, Fig. 14). Similarly, EPIC-μCT measurements 
showed a significantly higher 3D average marginal thickness in MMT animals compared 
to shams at week 2. EPIC-μCT also allowed for measurements of additional osteophyte 
parameters - total volume and mineral volume. Marginal total volume and mineral 
volume were all increased in MMT animals by 2 weeks post-surgery (Fig 14). 
Table 3.Average incidence of lesions and erosions in sham and MMT groups 




Figure 14.Osteophyte progression in MMT animals over 3 weeks. A. Osteophyte 
widths as calculated via histo-pathology scoring show an increase in MMT joints 
compared to shams at week 2 and week 3. B-D:  Marginal average 3D thickness (B), 
marginal total volume (C) and marginal mineral volume (D) as calculated via EPIC-
μCT show an increase in MMT joints compared to shams at week 2 and 3. n = 5-
6/group for CT data; n= 3 for sham and n = 5-6 for MMT for histology data. 
* = p < 0.05, sham significantly different from MMT at week 2; $ = p < 0.05, sham 
significantly different from MMT at week 3  
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A correlation analysis (Fig 15) was performed comparing EPIC-μCT 3D 
thickness and 2D histopathology tissue widths and a significant correlation was observed 





EPIC-μCT and histopathology analyses were performed on the sham, vehicle 
treated, and MMPi treated samples at 3 weeks post-surgery. Representative coronal 
sections from histology and EPIC-μCT coronal sections are presented from each group 
(Fig. 16). Similar degeneration, lesion formation and osteophyte appearance are observed 












Figure 16.Representative histology and EPIC-μCT images depicting effect of 
MMPi on MMT joints. A – B: Toluidine blue stained MMT joints showing reduced 
osteophyte formation in MMPi treated joint (B) compared to vehicle treated joint 
(A). C-D: Corresponding EPIC-μCT images for the samples as sectioned via 
histology indicating reduced osteophyte formation in MMPi treated joint (D) 
compared to vehicle treated joint (C). Red indicates higher attenuation 
corresponding to lower proteoglycan content 
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A significant decrease in the tibial 3 zone sum score, the osteophyte width, and 
the subchondral bone score was observed via histopathology scoring. Other parameters—
total cartilage degeneration, cartilage matrix loss at 0% depth, and total joint score—did 
not show a significant effect of MMPi treatment (Table 4) 
 
 
Cartilage attenuation as calculated via EPIC-μCT, increased at 3 weeks in the 
MMT+vehicle and MMT+MMPi animals compared to the sham controls (Fig. 17), 
though no difference was observed between the two MMT groups.  
 
Table 4. Histopathology data from MMPi study 
 66 
 
Figure 17.Tibial articular cartilage variables quantified for MMT joints treated with 
MMPi A. MMPi treatment significantly reduces 3 zone sum score compared to vehicle 
treated group B. Cartilage attenuation is significantly lower in sham group compared to 
both vehicle treated and MMPi treated groups C. Lesion volume is significantly reduced 
in MMPi treated group compared to vehicle treated group. n = 15-21/group 
* = p < 0.05, sham significantly different from vehicle &MMPi; $ = p < 0.05, vehicle 
significantly different from MMPi; # = p < 0.05, vehicle significantly different from 
sham  
 
EPIC-μCT was also used to measure lesion and erosion incidence, lesion volume, 
and subchondral bone volume (Table 5). Occurrence of lesions and erosions were not 
affected by MMPi treatment. However, lesion volume was significantly reduced in the 
MMT+MMPi group compared to the MMT+vehicle group. The shams showed no lesions 
on the cartilage.  
 
Table 5.Incidence of Lesions & Erosions in MMPi Study 
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Subchondral bone volume was also significantly lower in the MMT+MMPi group 
compared to the MMT+vehicle group (Fig 18).  
 
A significant decrease in 2D histology OP width was observed in MMPi treated 
animals compared to vehicle treated animals (Fig. 19). Sham animals did not have width 
measurements above the 0.2 mm cut off and were scored as zeroes as per the current 
standard. Quantitative EPIC-µCT similarly showed significantly reduced average 3D 
thickness, marginal total volume and marginal mineralized volume compared to the 
vehicle group (Fig. 19). Osteophytes were not detected in shams via histology or 
EPIC-µCT. 
Figure 18.Effect of MMPi on subchondral bone volume. MMPi treatment reduces 
subchondral bone volume compared to vehicle treated joints. * = p < 0.05 
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Power analysis  
A power analysis was performed to measure the minimum number of samples 
required to detect differences in cartilage degeneration and osteophyte development 
between the MMPi treated and untreated MMT groups (Table 6). Post-hoc power 
analysis based on total peripheral volume indicated that a minimum of 7 animals would 
be needed per group to detect a significant difference at a power > 0.8 and α = .05; while 
histology would require a minimum of 13 samples per group for osteophyte width 
Figure 19.Effect of MMPi on osteophyte development in MMT joints. A: 
Osteophyte widths as calculated via histo-pathology scoring are significantly 
lower in MMPi treated group compared to vehicle treated group B-D:  Marginal 
average 3D thickness (B), marginal total volume (C) and marginal mineral 
volume (D) as calculated via EPIC-μCT are significantly lower in MMPi treated 
group compared to vehicle treated group. n = 15-21/group 
* = p < 0.05, sham significantly different from vehicle &MMPi; $ = p < 0.05, 
vehicle significantly different from MMPi 
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(assuming experimental design would be equal between the groups). Other parameters 




Table 6.Post hoc power analysis 
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Discussion 
 Development of new and improved therapeutics for OA has been limited by 
techniques which are high in cost and low in throughput. Previously, we have developed 
EPIC-μCT as an imaging technique that can analyze cartilage quantitatively, efficiently 
and without destroying the sample (Thote, Lin et al. 2013). In this study we compared 
quantitative 3D EPIC-μCT results to the gold standard of 2D histopathology in the rat 
MMT model. We also showed that EPIC-μCT has the sensitivity to evaluate the efficacy 
of DMOADs in the rat MMT model and is more sensitive than the current gold standard 
of histopathology.  
In this study we showed that EPIC-μCT provides a fully quantitative analytical 
technique that is non-destructive, quantitative, and has highly sensitive parameters which 
can be evaluated over the entire region or can be focused on specific regions of interest. 
Histopathology scoring is semi-quantitative as it subjectively scores 2D sections. 
Sectioning, imaging and scoring samples is time consuming and the semi-quantitative 
nature of the technique results in requiring large sample sizes to detect significant 
differences. Using EPIC-μCT we were able to quantify cartilage attenuation, cartilage 
volume and thickness, occurrence of lesions and erosions, volume of lesions, osteophyte 
formation, and subchondral bone thickening.  
The 3 zone sum score measurement from histopathology showed a large discrete 
step increase between shams and the week 1 time point which did not significantly alter 
over the 3 weeks. In the case of EPIC-μCT a more continuous increase in cartilage 
attenuation was observed indicating that this parameter is more sensitive to PG changes. 
The 3 zone sum score is based on the PG loss at a singular location whereas attenuation 
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data is an average measurement for the entire cartilage within the selected region of 
interest(Gerwin, Bendele et al. 2010). This data may suggest that the lesion volume 
measurement may be more similar to the 3 zone sum score than attenuation though 
lesions are not detected in this model via CT until week 2.  
The results of the MMPi treatment showed that MMPi significantly decreased the 
3 zone sum score and lesion volume whereas cartilage attenuation was not affected. 
Though similarities exist between histopathology and EPIC-μCT, this finding calls 
attention to the fact that the parameters from the two different techniques are measuring 
different incidences. Additionally, histopathology also scores features such as 
chondrocyte proliferation, synovial hyperplasia and vascular infiltration which cannot be 
analyzed via CT(Gerwin, Bendele et al. 2010). However, since EPIC-μCT is non-
destructive of the samples, these features can still be analyzed via histology after the 
samples are scanned.  
Osteophytes occur on the joint margins, they are thickening of the marginal tissue 
observed in human OA as well as in the MMT model. Histopathology scoring of 
osteophytes involves scoring maximum thickness from three different regions . In this 
study, we presented a novel method of analyzing both the size and composition of 
osteophytes using EPIC-μCT. Histopathology findings showed an increasing osteophyte 
thickness which was also observed in EPIC-μCT data via an increase of 3D thickness and 
volume. EPIC-μCT also showed mineralization of the osteophyte by two weeks. This 
mineralization is difficult to view in histology sections as the sections usually need to be 
decalcified prior to sectioning. Mineralization of the osteophyte is another feature of 
human OA that similarly develops in the MMT model, though at a highly accelerated 
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pace. Osteophytes originate from activated periosteum which leads to new cartilaginous 
outgrowths that eventually mineralizes via endochondral bone formation. A possible 
mechanism for MMPi effect on OP progression could involve the role that MMP-9 and 
MMP-13 play in OA. MMP-9 and MMP-13 are highly expressed in osteoclasts and 
chondrocytes in arthritic cartilage and their inhibition via the MMPi could lead to 
reduced OP formation as the production of cartilage and bone is limited(Hayami, 
Pickarski et al. 2004).  Osteophyte progression could also be a sensitive parameter in 
evaluating therapeutic efficacy. In the MMPi treated rats, the most acute effect was 
observed in the reduction of the mineral volume of osteophyte. This result suggests that 
the MMPi might be more beneficial towards the later stage of OA progression, at least 
with regards to the osteophyte.  
One of the major limiting factors for screening DMOADs in pre-clinical animal 
models is the limited sensitivity of outcome techniques. Our post-hoc power analysis 
results showed that EPIC-μCT could reduce the number of animals required for drug 
screening. The most sensitive parameter in EPIC-μCT (Total OP volume) showed that 
only 7 samples per group would be needed whereas the most sensitive histopathology 
parameter (OP width) showed that at least 13 samples per group would be required. A 
lower number of animals would have a downstream effect resulting in faster data 
generation and lower amount of pharmaceutical compound synthesis at the initial stage. 
Moreover, EPIC-μCT is much faster as analyzing a single sample requires approximately 
2.5 hours whereas a full-scale histopathology study can take months to complete, with the 
decalcification procedure itself taking between 10-14 days. EPIC-μCT parameters could 
allow for in vivo screening in a rapid, efficient and quantitative manner while allowing 
 73 
for smaller sample numbers leading to reduction in time needed to identify potential 





THERAPEUTIC EFFECT OF MICRONIZED DEHYDRATED 
HUMAN AMNION/CHORION MEMBRANE (µ-dHACM) TESTED 





Micronized dehydrated human amnion/chorion membrane (µ-dHACM) is derived 
from donated human placentae and has anti-inflammatory, low immunogenic and anti-
fibrotic properties. This material has been previously used in the clinic in applications 
such as tendon repair and corneal epithelial defect but has not yet been tested in an OA 
model. The objective of this study was to quantitatively assess the efficacy of µ-dHACM 
as a disease modifying intervention in a rat model of OA. It was hypothesized that intra-
articular injection of µ-dHACM would attenuate OA progression.Lewis rats underwent 
medial meniscal transection (MMT) surgery to induce OA. µ-dHACM or saline was 
injected intra-articularly into both naïve and MMT joints.  To simulate clinical OA, rats 
were injected with µ-dHACM  3 weeks post-surgery as well and analyzed at 6 weeks. 
Denatured µ-dHACM was tested at the 3 week time point to examine effects of bioactive 
components. Microstructural changes in the tibial articular cartilage were assessed using 
EPIC-µCT and the joint was also evaluated histologically. There was no measured 




 Portions of this chapter were adapted from Willett N*, Thote T*, Lin AS, Moran S, Raji Y, Sridaran S, 
Stevens HY and Guldberg RE. Intra-articular injection of micronized dehydrated human amnion/chorion 
membrane attenuates osteoarthritis development. Arthritis Research &Therapy16(47). February 2014. 
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baseline effect of µ-dHACM on cartilage in naïve animals. µ-dHACM was sequestered in 
the synovial membrane following intra-articular injection and attenuated cartilage 
degradation in a rat OA model at 3 weeks and via a delayed injection at 6 weeks. 
Denaturation of µ-dHACM did not have a chondro-protective effect on the articular 
cartilage. These data suggest that intra-articular delivery of µ-dHACM may have a 
therapeutic effect on OA development.  
Introduction 
Multiple clinical trials have tested a number of potential disease modifying OA 
drugs (DMOADs), including matrix-metalloproteinase inhibitors (MMPis), cytokine 
blockers, inhibitors of inducible nitric oxide synthase (iNOS), and doxycycline; however, 
none have shown a clear therapeutic benefit to date (Martel-Pelletier, Wildi et al. 2012). 
There are various DMOADs in clinical trials such as rhFGF-18 (Sprimerfin by Merck), a 
growth factor based therapy, in Phase II which has shown a decrease in cartilage 
thickness and volume in patients with OA(Hellot, Wirth et al. 2013).  Strontium ranelate, 
in a recently completed a Phase 3 clinical trial showed a significant improvement in joint 
structure of OA patients (Reginster 2013). Though heavy investment in research 
continues, OA remains a pervasive and burdensome condition with limited effective 
clinical options, and there is still a critical need to investigate novel OA therapies.  
  Testing therapeutics for OA requires selection of a suitable animal model and an 
efficient and quantitative analysis method. The medial meniscal transection (MMT) rat 
model is a well-accepted small animal model for evaluating new pharmacologic agents 
(Gerwin, Bendele et al. 2010). Micro-computed tomography (µCT) imaging can rapidly 
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and quantitatively evaluate 3D morphologic and degenerative changes in articular 
cartilage by EPIC-µCT(Palmer, Guldberg et al. 2006).  
 Locally delivered extracellular matrix proteins are a promising treatment strategy 
being developed for a wide range of regenerative applications (Niknejad, Peirovi et al. 
2008). Dehydrated human amnion/chorion membrane (dHACM) is a tissue derived from 
donated placentae which possesses anti-inflammatory properties, displays low 
immunogenicity, and promotes wound healing while inhibiting scar formation (Faulk, 
Matthews et al. 1980, Akle, Adinolfi et al. 1981, Hao, Ma et al. 2000). There is an 
established precedence of using this tissue for regenerative applications clinically, 
ranging from corneal defects to tendon repair (Gruss and Jirsch 1978, He, Li et al. 2002, 
Mligiliche, Endo et al. 2002, Gajiwala and Gajiwala 2004, Chandra, Maurya et al. 2005, 
Thatte 2011). 
The potential for dHACM to modulate the development of OA has not been 
previously investigated; however indirect evidence suggests that it may have beneficial 
effects on cartilage. In vitro, dHACM has been shown to maintain chondrocyte 
phenotype when seeded with chondrocytes (Diaz-Prado, Rendal-Vazquez et al. 2010, 
I.H.Hussin, Pingquan-Murphy et al. 2011). In vivo, chondrocyte seeded dHACM 
enhanced regeneration of hyaline cartilage in rabbit osteochondral defects after 8 weeks 
(Jin, Park et al. 2007). One of the limitations of these previous studies has been the use of 
dHACM in the form of sheets which can only treat large defects and would require an 
invasive surgery. Micronized dHACM (µ-dHACM) offers a minimally invasive, 
injectable therapy with a longer shelf life than cellularized constructs. µ-dHACM can be 
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devitalized while preserving its basement membrane structure and a variety of growth 
factors including PDGF, FGF and TGF-β (Ji, Xiao et al. 2011).  
An injectable formulation of µ-dHACM (EpiFix® Injectable, MiMedx Group, 
Inc. Marietta, GA) has recently been developed that retains the active factors of the 
original tissue and allows for minimally invasive local delivery targeted to the disease 
site. µ-dHACM is developed after the native amnion undergoes the PURION process 
which maintains bioactive components despite the tissue being devitalized and 
dehydrated (US Patent 8,357,403– Placenta Tissue Grafts. US Patent 8,372,437-Placenta 
Tissue Grafts.14. US Patent 8,409,626-Placenta Tissue Grafts). The tissue retains the 
epithelial and chorion layer after the process.  A recent study examined the biological 
properties of µ-dHACM and in vitro experiments show quantifiable levels of various 
growth factors, interleukins and TIMPS(Koob, Rennert et al. 2013, Koob, Lim et al. 
2014). A subcutaneous in vivo experiment in the same study demonstrated recruitment of 
mesenchymal progenitor cells to site of implantation as well(Koob, Rennert et al. 2013).  
The applicability of this material as a therapeutic for OA has not yet been studied. 
The objective of this study was to quantitatively assess the efficacy of µ-dHACM as a 
disease modifying intervention in the rat MMT model and examine the effect of 
denaturation on the therapeutic effect of µ-dHACM. It was hypothesized that a single 
intra-articular injection of µ-dHACM would attenuate OA disease progression in the rat 





Materials and Methods 
Surgical Methods 
  Weight matched adult male Lewis rats (Charles River, Wilmington, MA) 
weighing 300-325g, were acclimated for 1 week. For the MMT surgery, the animals were 
anesthetized with isoflurane, and the skin over the medial aspect of the left femoro-tibial 
joint was shaved and aseptically prepared. The medial collateral ligament (MCL) was 
exposed by blunt dissection and transected to reflect the meniscus toward the femur. The 
joint space was visualized, and a full thickness cut was made through the meniscus at its 
narrowest point (Janusz, Bendele et al. 2002).The skin was closed with 4.0 Vicryl sutures 
and then stapled using wound clips. For the 3 week study, 24 hours post MMT surgery, 
either µ-dHACM (AmnioFix® Injectable, MiMedx Group Inc. Marietta GA) or saline 
was injected intra-articularly into the stifle joint of the left leg (n=5 per group, per time 
point). µ-dHACM was sourced from two different donors processed in two different 
batches. µ-dHACM was resuspended according to the product insert and injected into the 
articular joint space using a 25 gauge needle. Animals were euthanized at 3 days or 3 
weeks post-surgery. Naïve animals did not undergo any surgical procedure and were 
injected with µ-dHACM or saline. For the six week study,µ-dHACM was injected either 
24 hours post-surgery (single injection), 3 weeks post-surgery (delayed injection) or at 
both 24 hours and 3 weeks post-surgery (multiple injection) into the left leg.  Sham 
surgery was performed in rats as well where the MCL was transected but the joint was 
sutured without transecting the meniscus (n = 6-8 per group). MMT surgery with saline 
injection served as a control group.  Animals were euthanized 6 weeks post-surgery. For 
the denatured dHACM study,either µ-dHACM, denatured µ-dHACM or saline was 
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injected intra-articularly in the left knee 24 hours post-surgery. Sham surgeries were also 
performed as controls (n = 8 per group). Animals were euthanized 3 weeks post-surgery. 
The Georgia Institute of Technology Institutional Animal Care and Use Committee 
approved experimental procedures for these in vivo studies (IACUC protocol #A09007 
and IACUC protocol #A10218). The experimental design is listed in the table below 
(Table 7): 
Table 7. Experimental Design 
Study 1 – 3 week µ-dHACM study 
 
Groups (n = 5) 
Naïve + 
Saline 
Naïve +        
µ-dHACM 
MMT + Saline MMT + µ-dHACM 
Study 2 – 6 week µ-dHACM study 
 
Groups (n = 6-8) 





MMT +  
µ-dHACM 
@ 24 hrs 
 
(Single) 
MMT +  
µ-dHACM 
@ 3 weeks 
 
(Delayed) 
MMT +  
µ-dHACM 
@ 24hrs + 3 
weeks 
(Multiple) 
Study 3 – 3 week denatured µ-dHACM study 
 
Groups (n = 7-8) 
Sham MMT + Saline MMT +  
µ-dHACM 
MMT + Denatured 
µ-dHACM 
 
 µ-dHACM was manufactured using the proprietary Purion® process and is compliant 
with the American Association of Tissue Banks regulations for donor tissues (MiMedx 
Group, Inc. Marietta, GA). The process produces a dehydrated, devitalized amnion and 
chorion tissue graft which is then micronized, sterilized and can be suspended in saline 
(US Patent 8,357,403– Placenta Tissue Grafts; US Patent 8,372,437-Placenta Tissue 
Grafts; US Patent 8,409,626-Placenta Tissue Grafts).µ-dHACM was denatured by boiling 
the saline suspended µ-dHACM for 60 minutes. 
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Synovial Fluid Analysis 
 Rats were euthanized via CO2 inhalation at 3 days or 21 days post-surgery for both 
the naïve group and MMT surgery group for the 3 week study. Synovial fluid was 
collected by first injecting 100µl of saline intra-articularly using a 30 gauge insulin 
syringe, followed by aspirating approximately 50-100µl of the synovial fluid and saline 
using the same syringe. Synovial fluid was analyzed using the Quantibody® Rat 
Inflammation Array 1, a multiplex ELISA kit that quantitatively measured 10 rat 
inflammatory factors - IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-13, MCP-1, TNFα 
(RayBiotech, Norcross, GA).  
 
EPIC-µCT Analysis of Articular Cartilage 
  Articular cartilage structure and composition were quantitatively evaluated in the 
tibial plateau as described in our previous study (Thote, Lin et al. 2013). Scanco 
evaluation software was used to assess 3D morphological parameters and local 
attenuation. Dissected tibia were immersion fixed in 10% neutral buffered formalin for 
48 hours then stored in 70% ethanol until ready for scanning. Immediately prior to 
scanning, tibiae were immersed in 2ml of 30% Hexabrix™ 320 contrast agent (Covidien, 
Hazelwood, MO) and 70% PBS at 37°C for 30 minutes (Palmer, Guldberg et al. 2006, 
Xie, Lin et al. 2009). Samples were then scanned using a µCT 40 (Scanco Medical, 
Brüttisellen, Switzerland) at 45 kVp, 177 µA, 200 ms integration time, and a voxel size 
of 16 µm (Xie, Lin et al. 2009). Raw data were automatically reconstructed to 2D 
grayscale tomograms. These were rotated to sagittal sections, and the cartilage was 
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contoured and thresholded with global segmentation parameters (Gauss sigma - 1.2, 
support - 2, threshold - 175-225). Direct distance transformation algorithms were used to 
quantify 3D morphology (Hildebrand and Ruegsegger 1997, Laib, Barou et al. 2000, Xie, 
Lin et al. 2009). The subsequently generated 3D images were delineated into three 
volumes of interest (VOIs). For the MMT model, images were evaluated for: (1) Full 
articular cartilage in the proximal tibia including medial and lateral aspects, (2) Medial 
1/3 of the medial tibial plateau and (3) Focal lesions on the medial plateau only. Outcome 
measures included average articular cartilage thickness, volume and attenuation. 
Cartilage attenuation is a quantitative parameter that is inversely proportional to sulfated 
glycosaminoglycan (sGAG) content (Palmer, Guldberg et al. 2006). Degraded cartilage 
contains lower sGAG content and therefore higher contrast agent content and higher 
attenuation values (Xie, Lin et al. 2009). Two outcome measures were defined for 
evaluation of focal defects: erosion (defect depth extending to less than 50% of cartilage 
thickness) and lesion (defect depth extending to more than 50% of cartilage thickness) 
(Pritzker and Aigner 2010).  To define VOIs of focal lesions, manual contouring was 
performed in the isolated lesion area to account for the curvature of the surrounding 
cartilage tissue and exclude the subchondral bone and surrounding air. Within this VOI, 
segmented cartilage volume was subtracted from the total volume evaluated to compute 
lesion volume. For the 6 week study, osteophytes were also evaluated. Surface roughness 
and exposed bone area were calculated using a custom MATLAB script using images 





For the 3 day time point, the entire limb was harvested with knee joint intact, fixed 
in 10% neutral buffered formalin for 3-4 days, transferred to 70% ethanol, and stored at 
4°C. For the 21 day and 6 week time point, the tibiae and femora were harvested 
separately, dissected free of surrounding tissues, fixed in 10% neutral buffer formalin for 
3-4 days, transferred to 70% ethanol, and stored at 4°C.  For femoral dissections, care 
was taken to preserve the synovium, meniscus, and femoro-meniscal connective tissue. 
Following EPIC-µCT scanning, tibiae and femora were decalcified in Cal-Ex II (Fisher 
Scientific, Waltham, MA) for 14 days. Dehydrated samples were routinely processed into 
paraffin embedded blocks. For comparison with EPIC-µCT images, sagittal sections were 
Figure 20.EPIC-μCT images indicating focal defects in MMT ratsA. Representative 
image isolating erosion in MMT joint B. Attenuation map indicating erosion on the MMT 
joint (Inset shows zoomed in view of erosion) C. Representative image isolating lesion in 
MMT joint D. Attenuation map indicating erosion on the MMT joint (Inset shows 
zoomed in view of erosion) 
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cut at 5µm thickness. Sections were stained for sGAGs with a 0.5% Safranin-O (Saf-O) 
solution and a 0.2% aqueous solution of FastGreen as a counter-stain or with hematoxylin 
and eosin (H&E). 
Histological assessment of µ-dHACM and denatured µ-dHACM was performed via 
embedding the samples in histogel (Wong, Vosburgh et al. 2012). Briefly, µ-dHACM 
was mixed with histogel in an approximate 1:3 V/V ratio. This mixture was pipetted into 
a standard cryo cassette and flash frozen. The resulting block was routinely cryo-
sectioned and stained with H&E.  
 
In vitro study 
 Extracts for cell culture were acquired by incubatingµ-dHACM or denatured µ-
dHACM in DMEM without 10%calf serum at a concentration of 20mg of tissue per ml of 
medium for 24 hours. The tissuewas removed by centrifugation and the extract was 
sterilefiltered. 
 Adult human dermal fibroblasts (HDFa, Life Technologies Corp., Grand Island, NY) 
were plated on 96-wellplates for 24 hours in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% calf serum (GIBCO, Life Technologies Corp.).After 24 hours, 
the medium was aspirated from the wells and replaced with one of the following: basal 
media (DMEM lacking serum - control), complete media (DMEM plus 10% calf serum 
positive control) or DMEM containing extracts of dHACM at 10, 5 and 1mg/ml. After 72 
hours, the plate was washed to remove unattached cells and a CyQuant assay 
(MolecularProbes CyQuant, Life Technologies C7026) was performed to quantify the 




All quantitative data were expressed as mean ± standard error. Joint parameters 
between groups were evaluated using a one factor (left vs. right) ANOVA with Tukey’s 
test for post-hoc analysis. Joint parameters within the same group were compared 
between experimental and control knees using paired t-tests. Statistical significance was 
set at p< 0.05. All data were analyzed using GraphPad Prism software version 5.0 
(GraphPad Software, Inc., La Jolla, CA). 
Results 
Short Term 3 Week Study 
µ-dHACM Injected into Naïve Joints 
µ-dHACM was injected into naïve joints to assess the inflammatory response at 3 
and 21 days. Histology three days post-injection showed µ-dHACM particles 
incorporated into the adjacent synovial tissue (Figure 21). The material appeared as 
variably-sized fragments of multi-layered eosinophilic, fibrillar material. µ-dHACM 
fragments were surrounded by moderate inflammatory infiltrate consisting of 
macrophages, lymphocytes, and plasma cells indicating an inflammatory response to the 
xenogeneic material. No fragments were observed in control samples injected with saline, 
and these samples exhibited minimal hemorrhage or inflammatory cell presence in the 
synovial membrane.  
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At 21 days post-surgery, histological staining of µ-dHACM treated stifle joints 
showed the continued presence of µ-dHACM in the synovium along with inflammatory 
cells. At 21 days, a distribution of smaller sized dHACM particles appeared compared to 
the 3 day time point and a similar foreign body response was observed surrounding the µ-





Figure 21.Histological assessment of µ-dHACM injected in naïve rats at Day 3. A-D: 
Representative histology images of µ-dHACM treated naïve joints and saline treated. C-
D are zoomed in versions of regions of interest (black box) defined in A-B respectively. 
µ-dHACM visible at 3 days as fibrillar/eosinophilic material, indicated by black arrows 
(C). 
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Figure 11.Histological assessment of µ-dHACM injected in naïve rats at Week 3. 
A-D: Representative images of µ-dHACM treated MMT joints and saline treated 
naïve. C-D are zoomed in versions of regions of interest (black box) defined in A-B 
respectively. µ-dHACM fragments visible at day week 3 as indicated by black 
arrows (C). 
 
Synovial fluid showed a significant increase in Monocyte Chemoattractant 
Protein-1 (MCP-1) concentration in µ-dHACM treated joints compared to control joints 
at 3 days but no difference was observed at 21 days. MCP-1 levels significantly 







The othercytokines tested did not show any significant differences or were below 
the limit of detection (Table 8). Numerical values for all cytokines are presented in the 
following table. 
  
Figure 23.MCP-1 levels in µ-dHACM treated and saline injected naïve rats. MCP-1 
levels were significantly higher at 3 days in both saline and µ-dHACM injected groups 
compared to 21 days. MCP-1 level at 3 days was significantly higher in the µ-dHACM 
injected joints compared to saline treated joints. ** p <0.05 for MCP-1 levels at 3 and 21 
days for both groups.*  p<0.05 for MCP-1 levels at day 3 in saline injected and µ-
dHACM injected. n = 5. 
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Table 8.Cytokine ELISA data for naïve joints. Data represented as Mean ± std. dev. - 
indicates cytokine content lower than limit of detection 
 
Cartilage structure and composition were assessed at 21 days using EPIC-µCT. 
Representative 3D reconstructions of the cartilage with thickness heat maps appeared 
normal in structure in naïve animals treated with µ-dHACM or saline (Figure 24). 
Quantitative assessments of cartilage volume and thickness indicated no differences 
between saline and µ-dHACM treated joints (Figure 24). Similarly, cartilage attenuation 
showed no significant difference between saline and µ-dHACM treated joints, indicating 
no differences in PG content (Figure 24). No lesions or erosions were observed in saline 




Naïve joints (pg/ml) 
Day 3 Day 21 
Saline µdHACM Saline µdHACM 
IFNγ - - - - 






IL-2 - - - 153.85 
± 113.00 









IL-10 - - - - 











TNFα - - - - 
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Figure 24.Tibial articular cartilage variables quantified for µ-dHACM in naïve joints. A. 
Representative EPIC-µCT tibial articular cartilage thickness maps for µ-dHACM and 
saline injected samples in naïve joints. B. Average cartilage attenuation C. Average 
cartilage thickness D. Average cartilage volume measure at 21 days. No differences in 
cartilage parameters were observed between µ-dHACM and saline injected groups. n = 5. 
 
µ-dHACM Injected into MMT Joints 
MMT joints were injected with µ-dHACM or saline, and the effects on the joint 
and synovium were assessed at 3 and 21 days. Histological analysis showed µ-dHACM 
incorporated into the synovium at both time points. As observed in naïve joints, the 
amnion fragments were surrounded by moderate inflammatory infiltrate and appeared 
reduced in size at 21 days. No fragments were visible in saline treated MMT animals at 
either 3 or 21 days (Figure 25). 
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 In the saline treated MMT animals at 21 days, lesions and areas of erosion were 
evident along with diminished Saf-O staining of the tibial surface suggesting loss of PG 
content. In contrast, histological analysis of dHACM-treated joints showed a smooth 
cartilage surface with no lesions and strong Saf-O staining (Figure 26). Histological 
observations did not indicate any differences in cartilage morphology between the two 
groups at 3 days. 
Figure 25.Histological assessment of µ-dHACM  injected in MMT rats. A-D: 
Representative H&E stained histology images of µ-dHACM treated MMT joints 
and saline treated MMT joints. µ-dHACM visible at 3 days and 3 weeks as 
fibrillar/eosinophilic material as indicated by black arrows (A & 
C).Hypercellularity observed in area around µ-dHACM fragments. 
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Figure 26.Histological assessment of tibial articular cartilage in µ-dHACM  
injectedMMT rats. A-D: Representative Saf-O stained histology images of µ-
dHACM treated MMT joints and saline treated MMT joints. µ-dHACM treatment 
protected tibial articular cartilage from damage. Saline injected joints show 
decrease in PG content at Week 3 and surface damage (indicated by black arrows) 
Synovial fluid analysis did not show significant differences between cytokine 
levels and most cytokines were below the limit of detection (Table 9). Values are 







Table 9.Cytokine ELISA data for MMT joints. Data represented as Mean ± std. dev. - 





Day 3 Day 21 
Saline µdHACM Saline µdHACM 
IFNγ - - - - 
IL-1a - - - - 
IL-1b - - - - 
IL-2 - - - - 
IL-4 - - - - 
























EPIC-µCT was used to characterize cartilage and focal defects at 21 days. 
Representative planes and 2D EPIC-µCT attenuation heat maps of the tibial section from 
µ-dHACM treated MMT joints and saline injected MMT joints are presented (Figure 27). 
Qualitatively, MMT animals with saline injections displayed noticeable cartilage focal 
lesions and erosion sites.  In contrast, cartilage surfaces in µ-dHACM treated joints 
appeared more consistently uniform, and no lesions were observed.   
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Figure 27.EPIC-µCT pseudocolor attenuation map. Sagittal tibial section for a 
saline injected (A) and µ-dHACM injected (B) MMT joint. Red = higher 
attenuation values (lower PG content), green = lower attenuation values 
(higher PG content). Black arrows indicate focal defects. The µ-dHACM 
treated joints did not display lesions on the tibial articular cartilage surface. 
 
Quantitative EPIC-µCT at 21 days post-surgery showed that µ-dHACM treated 
joints had lower cartilage attenuation, indicating higher PG content, in the medial 1/3 of 
the tibial plateau compared to saline injected MMT joints. There was no significant 
difference between average attenuation values between naïve joints and µ-dHACM-
treated MMT joints, suggesting the treatment maintained PG content comparable to intact 
joints (Figure 28). MMT joints injected with saline had an average incidence of 2.8 ± 0.2 
erosion and 2.4 ± 0.4 lesion sites per medial tibial plateau with an average lesion volume 
of .00725 ± .005 mm
3
. µ-dHACM treated MMT joints displayed significantly fewer 





Medial 1/3 cartilage volume was also analyzed. A significant increase in cartilage 
thickness was observed in both saline treated and µ-dHACM treated samples compared 
to contralateral controls (Fig 29). There was also a significant increase in thickness 
between the µ-dHACM treated and saline treated samples.  
Figure 28.Tibial articular cartilage variables quantified for µ-dHACM in MMT joints. 
A. Average cartilage attenuation was significantly decreased in µ-dHACM treated 
MMT joints compared to saline injected MMT joints for the medial 1/3 tibial plateau. B. 
Average number of erosions was significantly decreased in µ-dHACMtreated MMT 
joints compared to saline injected MMT joints. No lesions were observed in the µ-
dHACM treated MMT joints. C. Average focal lesion volume in saline injected MMT 
joints.* p <0.05 & n =5. 
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Longer Term 6 Week Study 
EPIC-µCT was used to generate 2D EPIC-µCT attenuation heat maps of the tibial 
section from the experimental groups (Figure 30). Qualitatively, MMT animals with 
saline injections and single injections displayed higher attenuation (in red) compared to 
the sham, delayed and multiple injection group.  
 
Figure 29.Effect of µ-dHACM on cartilage thickness. Cartilage thickness significantly 
increased in µ-dHACM treated MMT joints and  saline injected MMT joints compared 
to contralateral control. Cartilage thickness for  µ-dHACM treated MMT joints was also 
significantly higher than saline injected MMT joints. $ = p < 0.05 compared to saline 
and µ-dHACM treated MMT joints. * p <0.05 & n =5. 
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The medial 1/3 region of the medial tibial plateau was evaluated for cartilage 
attenuation, subchondral bone volume and cartilage volume (Fig 31). Cartilage 
attenuation was significantly higher in the saline and single injection group compared to 
sham, delayed and multiple injection group. Subchondral bone volume was significantly 
higher in the saline and single injection group compared to the delayed injection group. 
The sham group showed a lower subchondral bone volume compared to saline, single and 
multiple injection groups. No significant differences in cartilage volume were observed.  
Figure 30.Qualitative EPICµCT pseudocolor attenuation maps. µ-dHACM on 
cartilage thickness.MMT (B) and Single Injection (C) samples showed higher 
attenuation compared to sham(A), delayed (D) and multiple injections (E). Red = 
higher attenuation values (lower PG content), green = lower attenuation values 




The entire medial tibial plateau was evaluated for osteophytes. Three parameters 
were measured – marginal total volume, marginal mineral volume and marginal 
cartilaginous volume (Fig 32). Saline and single injection groups had significantly higher 
marginal total & cartilaginous volume compared to sham and delayed injection groups. 
Figure 31.Medial 1/3 tibial articular cartilage variables quantified for µ-dHACM 6 
week study. A. Cartilage attenuation significantly increased saline and single injection 
group compared to sham, delayed and multiple injection group. B. Subchondral bone 
volume was significantly higher in the saline and single injection group compared to the 
delayed injection group and lower in sham compared to saline, single and multiple 
injection group. C. No differences were observed in cartilage volume 
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Marginal mineral volume was also higher in saline and single injection groups compared 
to sham.  
 
Surface roughness and exposed bone area was analyzed for the medial and medial 
1/3 tibial plateau (Fig 33). No significant differences were observed in medial surface 
roughness. Medial 1/3 surface roughness was significantly lower in sham and delayed 
injection groups compared to saline, single and multiple injection group.   
Figure 32.Osteophyte progression quantified for µ-dHACM 6 week study. A. Marginal 
total volume significantly increased in saline and single injection group compared to 
sham and delayed injection group. B. Marginal mineral volume significantly increased 
in saline and single injection group compared to shams. C. Marginal cartilaginous 
volume significantly increased in saline and single injection group compared to sham 
and delayed injection group. (* = p < 0.05) 
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Medial exposed bone was significantly higher in saline and multiple injection 
group compared to sham and delayed groups (Fig 34). Medial 1/3 exposed bone was also 
significantly higher in saline and multiple injection group compared to sham and delayed 
groups. Average exposed bone value for contralateral controls for medial exposed bone 
was .044 ± 0.023 and for medial 1/3 exposed bone was 0.025 ± 0.021. 
 
 
Figure 33.Quantification of surface roughness. A. No differences observed in medial 
surface roughness. B. Medial 1/3 surface roughness was significantly lower in sham and 
delayed injection groups compared to saline, single and multiple injection group 
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Histology images of coronal sections display cartilage damage in saline, single 
and multiple injection groups (Fig 35). Smooth cartilage surface is observed in the sham 
surgery group indicated by red staining of PGs on the cartilage surface. Chondrocytes 
appear in a loop structure in the delayed injection group.  
 
Figure 34.Quantification of exposed bone. A. No differences observed in medial 
surface roughness. B. Medial 1/3 surface roughness was significantly lower in sham and 
delayed injection groups compared to saline, single and multiple injection group 
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Figure 35.Histological assessment of tibia in µ-dHACM 6 week study. Representative 
H&E stained coronal tibial sections for sham (A), saline (B), single (C), delayed (D) and 
multiple (E) injections. A. Sham joints show no cartilage damage. B – C: Cartilage 
damage observed on surface, zoomed in image shows fibrillation of cartilage 
degradation. Zoomed in image shows fibrillation of surface group. D: Delayed injection 
shows protective effect and no surface damage is observed. Inset shows chondrocytes in 
a looped structure. E. Multiple injections shows moderate inhibition of cartilage damage 







Denatured µ-dHACM Study 
 µ-dHACM was denatured via heat treatment and histology was performed on 
histogel embedded µ-dHACM samples (Fig 36). µ-dHACM showed linear, fibrillar 
structure whereas denatured µ-dHACM appeared to be smaller. Webbing like structure 
was also observed in denatured µ-dHACM. 
 
Figure 36.H&E stained µ-dHACM. Top panel shows µ-dHACM in linear, fibrillar 
structure. Bottom panel shows denatured µ-dHACM that appears to be in smaller 
fragments. Webbing like structure also observed in denatured µ-dHACM.  
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 In-vitro cell culture human fibroblasts did not show a change in cell number via a 
CyQuant assay in response to denatured µ-dHACM (Fig 37). Cell number was 
significantly lower in both µ-dHACM and denatured µ-dHACM treated cultures 
compared to complete media.  
 
 
The medial 1/3 region of the medial tibial plateau was evaluated for cartilage 
volume, thickness and attenuation subchondral bone volume and cartilage volume (Fig 
38). Cartilage volume was significantly lower in sham compared to other three groups. 
Cartilage thickness was significantly lower in sham compared to other three groups as 
well but a significant increase in cartilage thickness was observed in the denatured µ-
dHACM group compared to µ-dHACM. Cartilage attenuation significantly increased in 
saline and denatured µ-dHACM compared to sham.  
Figure 37.In vitro cell culture data. Denaturation of µ-dHACM did not have an effect 
on cell number compared to normal µ-dHACM. Complete media treated cells were 




 Lesion volume calculations showed no lesions in the sham group. Lesion volume 
was also significantly lower in the µ-dHACM group compared to saline and denatured µ-
dHACM group (Fig 39).  
 
Figure 38.Medial 1/3 tibial articular cartilage variables quantified for µ-dHACM 6 
week study. A. Cartilage volume was significantly lower in sham compared to other 
three groups. B. Cartilage thickness was significantly lower in sham compared to other 
three groups. A significant increase in cartilage thickness was observed in the 
denaturedµ-dHACM group compared to µ-dHACM. C.  Cartilage attenuation 
significantly increased in saline and denatured µ-dHACM compared to sham compared 




 Histology images of the synovium surrounding the femur show retention of both 
µ-dHACM and denatured µ-dHACM in the synovium (Fig 40). The materialis 
fragmented and surrounding by infiltrating cells.  
Figure 39.Quantification of lesion volume. Lesion volume was significantly lower in 
sham compared to the other groups. Lesion volume was significantly reduced in  µ-




There is an unmet medical need for OA therapeutics as no DMOADs have been 
approved for clinical use. Extracellular matrices such as dHACM are a promising 
therapeutic strategy due to their mix of extracellular matrix proteins, growth factors, and 
anti-inflammatory factors (Ahmed and Burke 1983). Human dHACM allografts also have 
an established precedence in clinical applications ranging from corneal defects to tendon 
repair (He, Li et al. 2002, Chandra, Maurya et al. 2005). The objective of this study was 
to quantitatively assess the efficacy of µ-dHACM (EpiFix® Injectable) as a disease 
modifying intervention in a rat model of OA. 
Figure 40.Histological assessment of µ-dHACM and denatured µ-dHACM injected in 
MMT rats. Fragments of material are visible in both groups as indicated by black 
arrows. 
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 EPIC-CT image analysis provided 3D, non-destructive and quantitative 
evaluation of changes in articular cartilage composition and morphology. The EPIC-CT 
data showed a significant reduction in cartilage damage in the form of higher PG levels 
(lower average attenuation), fewer incidences of erosions and no lesions in the MMT 
joints treated with µ-dHACM. We also performed histology in this study to compare to 
our EPIC-CT results by embedding and processing samples in the sagittal plane. This is 
the first study to demonstrate the protective effect of a single intra-articular injection of 
µ-dHACM in the rat MMT OA model. 
µ-dHACM had not previously been injected into the joint space; therefore 
biocompatibility and inflammatory responses were evaluated. Histological analysis 
indicated moderate local hypercellularity at 3 days and which persisted at 21 days. This 
response was localized to regions surrounding the µ-dHACM particles and was not 
present throughout the synovial membrane. This agreed with synovial fluid analyses, 
which demonstrated an increase in MCP-1 for animals treated with µ-dHACM at 3 days 
which was then reduced by 21 days. This increase in MCP-1 in response to µ-dHACM 
was not observed in the MMT/saline animals. This could be due to the fact that the MMT 
surgery itself caused inflammation and masked the upregulation of MCP-1 caused by µ-
dHACM treatment. While MCP-1 can activate and recruit monocytes during 
inflammation, this pro-inflammatory state may even support a healing response 
depending on the types of monocytes/macrophages recruited (Mosser and Edwards 2008, 
Ding, Sun et al. 2009). We did not observe an upregulation in other pro-inflammatory 
cytokines. The initial analysis of the inflammatory response has some limitations as 
levels of most cytokines were below the limit of detection by the ELISA multiplex array.  
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This is likely a technical limitation due to the challenge of harvesting rat synovial fluid, 
sensitivity of the synovial fluid assay and the limited volume of fluid present in the joint 
cavity. Alternative methods to explore in the future for synovial fluid analysis include 
using filter paper absorbent to extract synovial fluid from the joint space and using a 
more sensitive ELISA such as magnetic beads based multiplex assays. Another reason for 
these aberrations could be due to fact that µ-dHACM is a xenograft that is being injected 
in the rat joint. Although we observed a mild to moderate mononuclear inflammation, we 
did not identify granulocytes, which would indicate a chronic inflammatory response.  
Our 6 week study showed some interesting results. This was the first study 
treating a pre-arthritic joint with µ-dHACM. Interestingly, multiple injections did not 
seem to have any added benefit compared to a single delayed injection (3 weeks post-
surgery). This could be due to animal variability or due to the fact that the animals had to 
be anesthetized and injected twice, with the injection itself causing some trauma to the 
joint. A single injection 24 hours post-surgery did not have a lasting benefit up to 6 
weeks. This could attributed to the clearance of particles from the joint space as histology 
at 6 weeks did not show the presence of µ-dHACM in the synovium (Data not shown). 
Based on previous data and other studies, it is known that lesions are formed on the 
cartilage surface by 3 weeks in the MMT model. However, no lesions were observed at 6 
weeks in the delayed injection group. Histological analysis does depict a more densely 
packed columnar structure with a bluish tinge in the delayed injection group compared to 
the sham. The structure of the chondrocytes with its slightly elongated and flattened 
nuclei indicates towards a mix of fibrocartilage with normal hyaline cartilage(Ross and 
Pawlina 2011). Studies are ongoing currently to take down animals 1, 3 and 7 days post 
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delayed injection to examine where the µ-dHACM particles are located and if the lesions 
are getting filled with a mix of fibrocartilage. 
Denaturation of µ-dHACM eliminated its therapeutic effect in vivo. However, in 
vitro denaturation did not affect cell number. For a more complete picture, additional 
assays to measure cell activity would be needed. A functional assay, such as a cell 
migration assay can help understand if there are bioactive factors still present or not after 
denaturation that influence cell behavior. Denaturation did change the gross morphology 
of µ-dHACM as observed via histology. The tissue was smaller and appeared to create 
web like structures. Despite the fragments being smaller, the denatured µ-dHACM was 
still retained in the synovium up to 21 days. Since a therapeutic effect was not observed 
but µ-dHACM was retained in the synovium, it indicates that there are components 
which were deactivated by denaturation and normally do contribute towards a chondro-
protective effect. Further studies are needed to characterize and compare the bioactive 
components in normal and denatured µ-dHACM.  
There are several possible mechanisms by which dHACM may modulate the 
progression of OA. A recent study used ELISA assays to analyze growth factor levels 
present in µ-dHACM and showed quantifiable levels of PDGF-AA, PDGF-BB, TGFα, 
TGFβ, basic fibroblast growth factor (bFGF), epidermal growth factor (eGF), placental 
growth factor (PLGF),  granulocyte colony stimulating growth factor, IL-4, IL-6,IL-8, IL-
10 and TIMP 1,2 & 4. The PURION process allowed µ-dHACM to retain its biological 
activity which may play a role in its effect on attenuation of OA in the rat MMT model.  
dHACM has  been shown to suppress the expression of potent pro-inflammatory 
cytokines, such as IL-1α and IL-1β, and also to decrease MMP levels through expression 
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of natural MMP inhibitors present in the membrane (Kim, Kim et al. 2000, Solomon, 
Rosenblatt et al. 2001). dHACM also contains IL-1Ra, a receptor antagonist for IL-1, a 
pro-inflammatory cytokine that has been shown to be upregulated in OA (Hao, Ma et al. 
2000). Two low molecular mass elastase inhibitors – secretory leukocyte proteinase 
inhibitor (SLPI) and elafin – are present in the dHACM, both of which exhibit anti-
inflammatory properties (Niknejad, Peirovi et al. 2008). Hyaluronic acid is also present 
and acts as a ligand for the CD44 receptor which is expressed on inflammatory cells and 
plays a role in adhesion capabilities of immune cells  (Niknejad, Peirovi et al. 2008).  In 
addition to anti-inflammatory molecules, devitalized µ-dHACM particles have been 
shown to retain a variety of bioactive substances including multiple growth factors such 
as PDGF and FGF (Ji, Xiao et al. 2011). PDGF and FGF-18 have previously been 
implicated in chondrocyte growth (Liu, Lavine et al. 2007). All of these potential 
mechanisms, including maintenance of cartilage homeostasis and reduction of 
inflammation and MMP expression, may be active contributing factors to the observed 
protective effect of µ-dHACM. dHACM also retains natural structural components such 
as collagens (types I, III, IV, V, VI), fibrinogen, laminin, nidogen and PGs. While these 
components clearly are important for the regulation and maintenance of normal 
chondrocyte metabolism, whether the extracellular matrix composition of dHACM 
directly affects OA is unclear (Jin, Park et al. 2007). However, retention of the active 
regulatory components may be influenced by the size and composition of the dHACM 
particles. 
While the mode of action of a disease modifying therapy is a key component to 
the efficacy, local retention of the factor is also thought to be critical. Retention is 
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particularly challenging when considering small molecule DMOADs. The particle size of 
the drug or carrier is critical since particles less than 6 microns are quickly filtered 
through intercellular gaps or phagocytosed by macrophages (Edwards 2011). Clinical 
studies measuring residence time of various NSAIDs delivered intra-articularly found the 
half-life to range from 1.1 to 5.2 hours (Owen, Francis et al. 1994). Alternatively, larger 
particles likely illicit an immune response or may cause physical damage to the articular 
surface (Martel-Pelletier, Wildi et al. 2012). In this study, the µ-dHACM particles 
sequestered in the synovial membrane at three days were large enough to prevent rapid 
clearance. Recent research has focused on extending the residence time of drugs in the 
joint cavity via the use of biomaterials including PLGA, albumin and bio-polymer based 
carriers. In pre-clinical models, drug release from PLGA particles has been reported to 
last up to 14 days, but once released, the drugs were rapidly cleared (Butoescu, Jordan et 
al. 2009). Although further studies are needed to elucidate release kinetics and assess 
whether extended residence time translates to increased duration of therapeutic activity, 
µ-dHACM presents a potential advantage over other intra-articular therapeutics due to its 
retention through 21 days in the synovium, though release kinetics of any active factors 
would also play a role. µ-dHACM thus has the potential to require less-frequent 
injections to treat OA.  
In conclusion, this is the first study demonstrating reduction in cartilage 
degeneration in a small animal OA model via a single intra-articular injection of an ECM 
based treatment derived from amniotic membrane. EPIC-µCT, used as an analytical tool, 
showed, by way of several quantitative metrics, a cartilage-protective role for µ-dHACM. 
µ-dHACM is a minimally manipulated and marketed allograft material which has been 
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shown to be clinically effective in a variety of applications (Sharma, Maria et al. 2011, 
Forbes and Fetterolf 2012)and now through this study, µ-dHACM is presented as a 
potential disease modifying OA therapy. 
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS 
Overall Summary 
 Developing and testing new DMOADs remains a pressing clinical need. This 
research would require improved diagnostic techniques and suitable outcome measures in 
pre-clinical animal models to enhance the drug development process. A variety of new 
therapeutics are being tested in pre-clinical models; however, this testing is time 
consuming, semi-quantitative and expensive. The lack of an objective, quantitative 
technique to analyze articular cartilage has limited the utility of testing different 
therapeutics in an efficient, standard manner.  EPIC-µCT is a unique and powerful tool 
with the ability to rapidly and quantitatively analyze articular cartilage in OA models.  
 Articular cartilage cannot be visualized via normal imaging methods due to its 
composition and analyzing the effects of a therapeutic on cartilage in a pre-clinical rat 
OA model via traditional imaging techniques is a challenge. Accordingly, the overall 
objective of this proposal was to examine two distinct treatment strategies for OA in a rat 
joint degeneration model using EPIC-µCT. The central hypothesis of this work was that 
EPIC-µCT could be used to establish quantitative outcome measures which would be 
sensitive to detect effects of therapeutics in the rat OA model.  
 To test our hypothesis, OA was induced surgically in the rat and two different 
therapies were tested in the model. First, we characterized two models of joint 
degeneration using EPIC-µCT in the rat – the MIA model and the MMT model (Aim I, 
Chapter 3). Our results indicated that the MIA model, even a low dose, causes global 
articular cartilage damage whereas the MMT model leads to focal areas of damage which 
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can be quantified via EPIC-µCT. We were able to define ROIs for the MMT model and 
establish outcome measures such as lesion volume and attenuation. Our results coupled 
with the fact that the MMT model is the most commonly used model for testing 
DMOADs, led us to selecting the MMT model for future experiments. Following this, we 
analyzed the sensitivity of the EPIC-µCT technique by testing a small molecule drug, an 
MMPi, in the MMT model (Aim II, Chapter 4). In this study, we analyzed earlier time 
points and were successfully able to detect changes in the articular cartilage as early as 
two weeks. Results of a power analysis showed that EPIC-µCT was more sensitive than 
histopathology based on certain parameters. We established multiple quantitative 
outcome measures using EPIC-µCT- cartilage thickness/volume/attenuation, subchondral 
bone volume, osteophyte thickness/volume and lesion/erosion incidence and lesion 
volume. Finally, building on these two studies we finally tested a novel ECM based 
therapeutic (µ-dHACM) in the rat OA model with EPIC-µCT as our diagnostic tool (Aim 
III; Chapter 5). The results demonstrated reduction in joint degeneration in response to a 
single intra-articular injection of µ-dHACM. More interestingly, µ-dHACM also slowed 
down the progression of OA in a pre-arthritic joint when examined at a longer time point. 
Denaturation of µ-dHACM led to loss of a chondro-protective effect. Overall, this thesis 
presents original research on using EPIC-µCT as a diagnostic tool for analyzing articular 
cartilage in combination with presenting a novel ECM based therapeutic that can slow 





Articular Cartilage Analysis in the MMT Model  
Aim I focused on characterizing the MMT model using EPIC-µCT. To our 
knowledge, this is the first instance of using contrast based imaging to evaluate this 
model and determine quantitative parameters. Our working hypothesis was that EPIC-
µCT could quantitatively detect degenerative cartilage changes in the MMT model. To 
test this hypothesis, we induced joint degeneration surgically in the MMT model and 
defined localized regions of interest to facilitate detection of cartilage changes and 
compared the results to contralateral joints.  We followed this study with Aim II, where 
we analyzed the effects of a small molecule based MMPi on the articular cartilage to 
determine the sensitivity of the EPIC-µCT technique and compared it to traditional 
histopathology results.  
 Our results from Aim I for the MMT model contradicted some of the previously 
published results in literature. An increase in cartilage volume and thickness was 
observed in the MMT joints compared to contralateral controls. This was interesting as 
the expected and most commonly observed result observed via histology is thinning of 
the articular cartilage, a hallmark of OA. This “thickening” effect of the cartilage in an 
arthritic joint was detected by EPIC-µCT. There are a couple of reasons why it has not 
been observed commonly in the past. First, histology processing involves dehydrating 
samples. Since cartilage is mostly water, this thickening effect would be difficult to 
detect. Second, histology measurements are 2D and are based on only a few slices per 
sample to get representative values. EPIC-µCT, however, provides a complete 3D 
analysis and the sample is not dehydrated. We believe that the cartilage thickening effect 
observed was in response to the MMT surgery, where the PG network is loosening and 
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will eventually lead to cartilage degeneration. Our 6 week data in Aim III, did show large 
areas of surface damage and a lower degree of cartilage thickening compared to our 3 
week study. Another factor that could be contributing the increase in cartilage thickness 
is marginal osteophyte growth. 
 Osteophytes are another characteristic of OA, which we evaluated in Aim II. The 
EPIC-µCT analysis was performed on sagittal sections as our volume of interest was the 
medial tibial and medial 1/3 of the medial tibial plateau. Osteophytes grow on the 
periphery of the cartilage and can be observed on coronal slices. Delineating the cartilage 
in the sagittal sections could have included portions of the osteophyte on the margins 
which could also lead to an increase in the value of cartilage thickness/volume 
measurements. One of the most interesting results with regards to OP was the visible 
progression of mineralization. Mineralization in OP, particularly at early time points such 
as 2 weeks is difficult to detect via histology due to decalcification of samples. In human 
OA, as the disease progresses, the OP gets mineralized eventually showing up on x-rays 
as bone spurs. The MMT model, while does show OP progression does not show bone 
spurs at least at a 6 week time point.  
 The MMT model though widely used does also have certain limitations. One, the 
model presents a continued destabilization of the joint which is challenging for a 
therapeutic to overcome. Longer term studies in this model, even the 6 week time point 
(Aim III) showed extensive cartilage damage. Since the meniscus can never be repaired, 
the continuous loading of the joint would lead to cartilage damage which even an 
effective therapy cannot reverse. In humans, in case of a meniscus tear or similar injury, 
the joint is usually stabilized externally and less weight is put on the joint. In rats, the 
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continuous movement can make it difficult to necessarily observe a significant 
therapeutic benefit. A recent study showed that the transection of the meniscus also does 
not lead to a functional deficit as measured by gait analysis until 8 weeks(Allen, Mata et 
al. 2012). With OA, there isn’t a strongly coupled structural-function relationship as often 
there are patients whose x-rays show no anomalies but suffer from pain and there are 
cases with patients with bone spurs only having mild pain. The lack of an earlier 
functional response in this model renders it unsuitable for analyzing pain. Using both the 
MIA and MMT model to evaluate a therapeutic could be useful to examine a pain 
response and disease modifying response, respectively. EPIC-µCT can still be used as a 
diagnostic tool for articular cartilage analysis with additional measures such as histology 
for cellular behavior and gait analysis for functional assays.  
 EPIC-µCT provides various parameters that can be evaluated in response to a 
therapeutic though certain limitations exist. EPIC-µCT scans are at a 16μm voxel size 
which is not high enough to examine cellular morphology or microscopic changes. 
Histology can provide additional parameters including cellularity. There may be surface 
damage lower than 16um which cannot be analyzed by EPIC-µCT. Real-time 
longitudinal analysis via contrast based imaging is an area that is being explored by 
various groups but the resolution and segmentation remains a challenge. Piscaer et al. 
performed in vivo EPIC-µCT arthrography in a high dose MIA model and were able to 
show changes in cartilage volume and attenuation(Piscaer, Waarsing et al. 2008). 
However, equilibrium of the contrast agent was not achieved and it was not possible to 
have a standard threshold measure to discriminate between the cartilage and underlying 
calcified cartilage bone layer (Piscaer, Waarsing et al. 2008). Being able to analyze the 
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cartilage longitudinally will significantly reduce number of animals required and help 
understand real time effects of various therapeutics.  
 This work has advanced our knowledge about the MMT model and the suitability 
of EPIC-µCT as an imaging technique. Ongoing work in the lab includes shorter time 
points for the MMT surgery and utilizing MATLAB to write custom programs to perform 
surface analysis in addition to EPIC-µCT outcomes. Future work involves translating the 
MMT model to a larger animal (sheep) and developing suitable EPIC-µCT imaging 
methods to analyze the cartilage. We are also trying to optimize the technique using a 
uCT50 scanner of 8μm resolution to analyze murine cartilage. This will open up the area 
to test therapeutics in transgenic mice as well as use knock-out OA models for analysis.  
 The use of EPIC-µCT in this thesis has been limited to articular cartilage analysis 
in the MMT model. The technique can be extrapolated to other applications as well 
including but not limited to osteochondritis dissecans(OCD), intervertebral disc 
disorders, micro-fractures and cartilage explant models. This would require optimizing 
the technique for the particular application in terms of equilibration times, concentration 
of contrast agent, selecting suitable VOIs but it is a possibility. Current work in the lab 
includes developing an OCD model in the rats and using EPIC-µCT to analyze it. With 
suitable outcome measures, EPIC-µCT provides a new platform for cartilage analysis in a 
rapid, quantitative and efficient manner.  
Mode of Delivery 
 In this study we used two modes of drug delivery - oral delivery of MMPi and 
intra-articular delivery of µ-dHACM. Oral delivery allows for controlling the dose and 
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having a formulation that can be ingested. Intra-articular delivery allows for localized 
injection but is limited by half-life and retention rates in the joint space. 
 The current line of treatment, NSAIDs and COX-2 inhibitors are mostly delivered 
orally. However, this has led to side effects including GI ulcers and bleeding (Janssen, 
Mihov et al. 2014). Several MMPi's have been tested in clinical trials but none have been 
successful yet due to lack of efficacy and unfavorable risk-benefit profile (Fingleton 
2007). There is also the challenge of bio-availability via oral or systemic delivery 
(Janssen, Mihov et al. 2014). Assessment of therapeutic index for MMPi's which is the 
ratio of dose required for efficacy vs. toxicology is challenging and systemic delivery 
necessitates the use of a larger dose (Peterson 2006). This has led to research for alternate 
methods to deliver therapeutics. Intra-articular (IA) drug delivery is clinically used for 
compounds such as hyaluronan. This mode is limited due to its invasiveness and a 
maximum of four injections/year are allowed (Hinton, Moody et al. 2002). Half-life of 
compounds in the knee joint and rapid clearance rates are limiting factors for this.  
 In our study, 30mg/kg of MMPi was delivered orally every day which showed a 
therapeutic benefit in-vivo.  In the case of µ-dHACM, a single IA injection at 80mg/ml 
suspended in 50μl saline, showed a therapeutic benefit as well. Though the same drug 
was not used in both the experiments and a direct comparison is not possible, the fact that 
a lower amount of therapeutic was needed intra-articularly is not surprising.  
 Oral/systemic delivery requires a greater dose leading to higher risk of side-
effects. IA delivery allows for localized injection where the effects of the drug are mostly 
restricted to the joint space. A key factor for suitable IA delivery is size which affects 
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retention rate. The presence of synovial fluid in the joint leads to clearance of particles 
from the joint space if they are too small. If the particles are too large, that can cause 
irritation in the joint and lead to inflammation (Gerwin, Hops et al. 2006). µ-dHACM 
was retained in the synovium and this could be due the fact that it possesses fragments of 
natural ECM in its matrix.  
 Choosing a mode of delivery is dependent on the structure and mechanism of 
action of the therapeutic. The MMPi treatment is a small molecule which could not be 
retained in the joint without a suitable delivery vehicle whereas µ-dHACM is an ECM 
based therapeutic that could not be ingested orally. Longer term effects and toxicology 
studies for both the MMPi and µ-dHACM can help understand if the selected mode is 
optimal and what parameters might need to be modulated for effective delivery.  
Therapeutic Effect of µ-dHACM 
The search for effective DMOADs is a very active area of research. There are at 
least 12 DMOADs that are in human clinical trials currently, most of them delivered 
orally (Hunter 2011). Fibroblast growth factor 18 (FGF-18) demonstrated cartilage repair 
in the rat MMT model and is currently in clinical trials as well (Beenken and 
Mohammadi 2009). We took an ECM based therapeutic approach in the form of u-
dHACM to test its effect on the articular cartilage as listed in Aim III. Our working 
hypothesis was that intra-articular delivery of µ-dHACM (EpiFix™ Injectable) will 
ameliorate the progression and extent of joint degeneration in the rat MMT model and 
based on our results from Aim II, EPIC-µCT would be able to assess changes in the 
articular cartilage in response to µ-dHACM. We tested this hypothesis by injectingµ-
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dHACM in MMT rats 24 hours post-surgery and analyzing cartilage at 3 weeks. We also 
examined longer term effects at 6 weeks, delivering µ-dHACM 24 hours and/or 3 weeks 
post-surgery. Finally, we denatured µ-dHACM to see if denaturation of the matrix leads 
to a loss of therapeutic benefit.  
Our data showed some very promising results of µ-dHACM as a DMOAD in this 
pre-clinical study. In the 3 week study, a single intra-articular injection of µ-dHACM led 
to inhibition of lesion formation in the treatment group. In the MMT model, if the surgery 
is performed correctly, all joints develop lesions by 3 weeks which has been observed in 
multiple studies(Bendele 2002, Moore, Bendele et al. 2005, Gerwin, Hops et al. 2006, 
Gerwin, Bendele et al. 2010). The inhibition of these lesions was a very potent effect of 
µ-dHACM, that too with just a single injection. Histology showed retention of µ-
dHACM fragments in the synovium up to 3 weeks post injection suggesting that this 
presence might be important for a therapeutic response. Injecting µ-dHACM 24 hours 
post-surgery can help delay the onset of OA as indicated in the 3 week study. This could 
be useful in situations of post-traumatic OA. Individuals with joint injuries such as ACL 
transection, meniscal tear are more prone to OA. Post-traumatic OA is prevalent in the 
military population with joints suffering from war injuries leading to 60% rate of OA and 
with a 100% rate of OA following knee injury (Rivera, Wenke et al. 2012). Exploring the 
applicability of pre-treatment withµ-dHACM to delay the onset of post-traumatic OA is 
another area of interest.  
Based on our 3 week study results, we wanted to test what would happen at a later 
time point of 6 weeks in case of a single injection (24 hours post-surgery), delayed 
injection (3 weeks post-surgery) and multiple injection (24 hours and 3 weeks post-
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surgery). Our 6 week results were surprising, as the delayed injection group showed the 
greatest therapeutic benefit whereas the multiple injection did not perform any better than 
the delayed. The single injection did not have any therapeutic benefit at 6 weeks. It is 
important to note that the MMT model is an aggressive model, and the ability of µ-
dHACM to show a chondro-protective effect at 6 weeks was very promising. The lack of 
a benefit of multiple injections was unexpected though. One reason could be animal 
variability or the invasiveness of the injection since the animals had to be anesthetized 
twice and injected into joint space. Histology at 6 weeks did not show retention of µ-
dHACM in the joint space. This could be due to the aggressive nature of the MMT model 
and increased clearance rates through the joint as the disease progresses. As the disease 
caused more degradation at 6 weeks, we had to include new parameters for EPIC-µCT 
analysis. Lesion volume calculations were not possible as extensive degradation was 
observed in the saline injected MMT joints making it difficult to delineate suitable 
contours. Hence, exposed bone area was calculated using a custom MATLAB program. 
The reasoning behind conducting a 6 week study, though the standard is 3 weeks in the 
field, was to simulate human OA. In the clinic, patients start taking therapeutics after pain 
and damage has already started(Hunter, Guermazi et al. 2013). The delayed injection 
simulates treatment of a pre-arthritic joint as by 3 weeks cartilage damage is already 
observed in the MMT model.  
µ-dHACM presents itself as a potential DMOAD candidate but the mechanism 
behind its working is still unclear. In this thesis, the focus was to test EPIC-µCT as a 
diagnostic tool for articular cartilage analysis. We used it to examine the effects of µ-
dHACM and saw promising results. Denaturing µ-dHACM was the first step to examine 
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the role that growth factors and cytokines might play. Denaturation of µ-dHACM was 
performed via heat treatment and histology results indicate changes in the µ-dHACM 
structure. Though the results did show that denatured µ-dHACM did not have a 
therapeutic benefit similar to µ-dHACM, it is difficult to conclude if this was due to 
change in structure or depletion of GFs. In vitro results were inconclusive as well since 
cell proliferation was not affected by the denaturation process. In this study, only one in 
vitro assay was performed which does have limitations. For a more complete picture on 
the role of GFs and cytokines, additional assays to measure GFs in extract and cell 
culture would be needed. A functional assay, such as a cell migration assay can help 
understand if there are bioactive factors still present or not after denaturation. Further 
work is needed to tease out the role that GFs might play.  
There are multiple lines of future work involved with µ-dHACM. One includes 
performing a time course experiment to determine how long µ-dHACM is retained in the 
synovium and examining if there is a correlation between retention period and therapeutic 
benefit. We are currently performing additional histology on the delayed injection study, 
by taking down animals 1, 3 or 7 days post injection (where the injection is 3 weeks post-
surgery). This would help understand if µ-dHACM is being retained in the joint space 
and if it is filling up the pre-existing lesions that develop at 6 weeks. Our lab has also 
performed experiments with different formulations of µ-dHACM, where one formulation 
removes the epithelial layer during the production process (Unpublished data). This can 
shed light on the role of the epithelial layer with its different constituents on the chondro-
protective effect. We have also looked at different size formulations including super-
micronized µ-dHACM to see if the size of the original particles affects the articular 
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cartilage (Unpublished data). To understand the mechanism of µ-dHACM, in vitro assays 
would be essential. Contrary to our expectations, denaturation did not provide concrete 
conclusions towards the role of GFs. Inhibition of GFs implicated in OA and present in 
µ-dHACM  (ex: PDGF, FGF, EGF) via small molecules with appropriate controls in vitro 
could be a first step. This could be translated in vivo by injecting µ-dHACM pre-
incubated with these inhibitors. Another step could be decellularizing µ-dHACM 
followed by testing it in vitro and in vivo. The PURION® process devitalizes the amnion 
matrix but does not actively decellularize the material. A study by Bhatia et al. 
demonstrated elimination of growth factors and cytokines after decellularization of 
human amniotic membrane(Bhatia, Pereira et al. 2007). Another study showed a 
significant decrease in collagen, GAG, elastin, DNA and matrix hydroxyproline upon 
decellularization as well (Wilshaw, Kearney et al. 2006). Comparing and characterizing 
denatured, decellularized µ-dHACM and normal µ-dHACM and its responses in vivo 
could help understand the therapeutic effect observed. Additionally, the outcome 
measures so far have focused on articular cartilage. Analyzing the inflammatory and 
immune response would also be important in the future. One limitation is that µ-dHACM 
is human derived material which would always elicit some form of 
inflammatory/immune response in the rat model. Also, the MMT model causes 
inflammation as well and sham surgeries would be required as a control to compare 
responses in various groups. Another avenue to explore would be testing µ-dHACM in 
the MIA model to evaluate effects on pain. There are plans to translate this work to a 
larger animal model, in the sheep, in collaboration with San Antonia Military Medical 
Center (SAMMC). 
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There is no published work from other groups on the utility of µ-dHACM as a 
DMOAD. This is a clear area for future investigation in light of the results observed in 
the rat MMT model. As with in vivo models, it is important to understand the limitations 
of the selected model. OA in rats translates to a functional deficit much later than large 
animal models. Additional outcome measures other than EPIC-µCT need to be 
considered now that µ-dHACM has passed the initial screening process of having a 
positive effect on the articular cartilage. By designing suitable experiments with 
appropriate controls, we can advance our understanding of µ-dHACM and the role it 
plays on articular cartilage. This can open the area towards exploring ECM based 




In conclusion, the results demonstrate the utility of EPIC-µCT as an innovative 
tool to quantitatively analyze articular cartilage in a pre-clinical OA model. Multiple 3D 
parameters were established that can quantify localized damage in the MMT model and 
used as outcome measures to test therapeutic efficacy. The ability of this technique to 
screen DMOADs was demonstrated by testing an MMPi and discerning its therapeutic 
effects on articular cartilage. A novel ECM based material - µ-dHACM is also presented 
as a potential DMOAD in this thesis. This is the first instance that shows an ECM based 
therapeutic ameliorating OA progression via a single intra-articular injection. Moreover, 
a delayed injection slowed the rate of disease progression in a pre-arthritic joint which 
has not been observed previously. Taken together, the results suggest that EPIC-µCT can 
be successfully used to screen for DMOADs and µ-dHACM is one such screened 




EFFECT OF PREGNANCY ON PROGRESSION OF JOINT 





OA is a progressive joint disease characterized by loss of cartilage, sclerosis of 
subchondral bone, formation of osteophyte and inflammation of synovial membrane due 
to imbalance in production and degradation of the cartilage extracellular matrix (Goldring 
and Goldring 2007).  
Multiple factors have been proposed to be involved in the initiation and 
progression of OA, such as injury, age, gene, sex and obesity (Goldring and Goldring 
2007). Local factors, such as the curvature and lubrication of articular cartilage, load 
bearing, alignment of low limb, have been well studied, while systemic factors have yet to 
be well investigated due to their complexity. Systemic factors such as age, gene and 
gender have been proposed to regulate ageing and rejuvenate blood and other 
tissues(Mayack, Shadrach et al. 2010). These factors have been proposed to be implicated 
in OA. Genetic factors are influenced by gene. The candidate genes associated to OA are 
variant between men and women (Valdes, Loughlin et al. 2007). The incidence of OA 
disease peaks with the age being > 30 in men and > 50 in women (Claassen, Schicht et al. 
2011).Menopause in women has also been co-related with a higher incidence of OA 
prevalence (Claassen, Schicht et al. 2011). It is associated with significant systemic 




 Portions of this chapter were adapted from Zhang K*, Thote T*, Leng H, Guldberg RE, Ge Z. Effects of 
Pregnancy on Progression of Osteoarthritis Induced by Monosodium Iodoacetate in Rats.  
JMBE33(5): 449-454. 2013. (* Co-first authors) 
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physiologic changes, such as regulation of immune response and changes in hormones 
(estrogens, progesterone, prolactin, and androgens). 
Pregnancy is involved in significant change of hormones, metabolism, and gene 
expression. Pregnancy has also been reported to suppress expression of both synthetic 
and degradative genes, including type II collagen, biglycan, TGF-β, collagenase, TIMP-1, 
IL-1β, TNF-α, iNOS and COX-2 (Hellio Le Graverand, Reno et al. 1998, Hellio Le 
Graverand, Reno et al. 2000). Based from these studies, it is reasonable to hypothesize 
that pregnancy, as well as subsequent physiological changes may affect the progression 
of OA.  
 OA can be induced through various methods such as via surgery, chemical 
injection, mechanical overuse or through spontaneous genetic OA models. Injection of 
monosodium iodoacetate presents a method of chemical induction of OA that is well 
characterized and has been extensively used in relation to examining joint pain in 
rats(Guzman, Evans et al. 2003).  In the current study, OA was induced in Wistar rats 
using a low dose of MIA based on previous studies (Janusz 2001). EPIC-μCT was used 






All animal experiments were operated in Animal Center of Peking University, 
which has been approved by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AALAC). Twenty female Wistar rats aged 12 weeks weighting 
280-300g were divided into four groups, and five adult male rats were used to mate with 
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female rats. All the animals were housed in sterile animal rooms with controlled 
temperature and humidity. The animals were divided into four groups: A – Pregnancy + 
MIA, B – Only MIA in naïve rats, C – Only pregnancy and D – Saline injections in naïve 
rats. MIA (I2512, Sigma-Aldrich, St. Louis, MO) injection was injected into the intra-
articular joint space of the female rats on the day of detection of vaginal plug. The rat 
knee joint was injected with 0.3 mg MIA in 50µL saline with a 27 gauge needle after 
pregnancy was confirmed. Group B received the same dose of MIA. Group C (only 
pregnancy) and group D (sham group) received saline injections. All the rats were 
euthanized on day 18 via CO2 inhalation. 
 
Macroscopic score 
Rat limbs were harvested after sacrificing the rats and the left legs were fixed in 
10% neutral buffered formalin for 48 h. The rat joint was dissected and surrounding 
tissue was excised. Images were taken using a digital camera (DSC-H10，Sony) and 
these macroscopic images were evaluated by two people in a blinded evaluation. The 
cartilage was assessed using a scoring system with a range of 0–4. Increasing score 
represented increasing severity of OA (0 represented normal appearance; 1 represented 
slight yellowish discoloration in the surface; 2 represented little erosions in load-bearing 
zone; 3 represented large erosions extending to the subchondral bone; and 4 represented 
large erosions with subchondral bone exposure (Janusz 2001). The scores were added and 




EPIC-µCT was performed as listed in Aim I. Briefly, the proximal end of each 
tibia was immersed in 2ml of 30% Hexabrix 320 contrast agent (Covidien, Hazelwood, 
MO) and 70% ion-free PBS at 37ºC for 30 minutes, an incubation period known to result 
in equilibration of the agent (Palmer, Guldberg et al. 2006, Xie, Lin et al. 2009). 
Proximal tibiae were blotted dry and scanned using a µCT 40 (Scanco Medical, 
Brüttisellen, Switzerland)at 45 kVp, 177 µA, 200 ms integration time, and a voxel size of 
16 µm (Xie, Lin et al. 2009). Scanco evaluation software was used to assess 3D 
morphology and composition. Raw scan data were automatically reconstructed to 2D 
grayscale tomograms.  
 
GAG Quantification 
For quantification of the GAG content, fresh tibial cartilage from the right knees 
of the rat joints was harvested using a scalpel, weighed and flash freezed using liquid 
nitrogen. The lyophilized sample was digested with 0.5 mg/mL proteinase K (P2308, 
Sigma) in 100 mM K2HPO4 at pH 8.0 in 56°C overnight. The digested sample was added 
to 1, 9-dimethylmethylene blue solution (DMMB, 341088, Sigma-Aldrich, St. Louis, 
MO), shaken for 30 min, and then centrifuged at 10,000g to separate the precipitate. The 
precipitate was dissolved with a dissociation reagent and the absorbance was measured at 
a wavelength of 656 nm in a microplate reader (680, Bio-rad, Japan). The standard of 
GAG content was constructed using chondroitin sulfate (C4384, Sigma-Aldrich 




Statistical analysis  
All the data are presented as mean ± SD. SPSS V13.0 (SPSS Inc., IL, USA) was 
used to analyze the data, and one-way analysis of variance (ANOVA, LSD) was utilized 
to compare the pregnancy + MIA, MIA, pregnancy and sham groups. The statistical 





There were no signs of infection in all experimental animals during the entire  
experiment. The tibial plateaus were smooth without any observable damage in the rats 
from group A (Figure 1A), group B (Figure 1B), group C (Figure 1C) and group D 
(Figure 1D). No chondral erosions were observed and neither did erosions appear in the 
load-bearing areas. No statistical significance could be detected in group A, B, C and D 
based on macroscopic scoring.  
 
 
Figure A.1. Macroscopic image of tibial cartilage in (A) Pregnancy+MIA; (B) MIA; 
(C) Pregnancy; (D) Sham groups. 
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μCT 
EPIC-µCT was used to measure cartilage attenuation and volume. No significant 
difference was observed in cartilage volume between groups. Cartilage attenuation was 
significantly higher in Pregnancy + MIA and MIA groups compared to Pregnancy and 
Sham groups(Figure A.2).  
 
GAG Quantification 
MIA induced low GAG content of cartilagein rat OA model.GAG amount was 
significantly higher in Pregnancy and Sham groups compared to Pregnancy + MIA and 
MIA groups( Figure A.3.).  
Figure A.2. EPIC-μCT measurements of articular cartilage. A. Cartilage volume was 
not significantly different between groups. B. Cartilage attenuation was significantly 
higher in Pregnancy + MIA and MIA groups compared to Pregnancy and Sham 
groups 





Pregnancy is a complex physiological process accompanied with changes in the 
hormonal level. It has been implicated in playing a role in the regenerative capacity of 
certain tissues and cells. In this study, the focus was to examine the effect of pregnancy 
on the progression of OA.  
Multiple  factors are involved in the initiation and progression of OA, and 
estrogen is one of these. Estrogen receptors have been found in cartilage, immortalized 
chondrocyte cell lines and in primary chondrocytes (Claassen, Schicht et al. 2011). This 
suggests that cartilage is a potential target for estrogen. However, the relationship 
between estrogen and OA remains inconsistent. Some studies found that there was no 
direct relationship between estrogen and OA. Estrogen treatment did not have an effect 
on the severity of OA in ovariectomized animals and deletion of estrogen receptors did 
not cause overt cartilage damage (Ham, Oegema et al. 2004, Ma, Blanchet et al. 2007, 
Figure A.3. GAG quantification of articular cartilage. GAG content was 
significantly lower in Pregnancy + MIA and MIA groups compared to Pregnancy 
and Sham groups 
* = p < 0.05, n = 5 
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Sniekers, van Osch et al. 2009). On the other hand, some results indicated that estrogen 
had protective effects on OA. OA was elevated with estrogen deficiency and estrogen 
therapy preserved cartilage(Tanko, Sondergaard et al. 2008, Roman-Blas, Castaneda et 
al. 2009).Contrarily, some results suggest that estrogen has negative effects on OA. 
Estrogen treatment caused synovial estrogen and estradiol receptor bindings to be 
increased, which induced cartilage degeneration and cell death, leading to the 
development of knee OA (Silberbe.R 1971, Tsai, Liu et al. 1992). As the relationship 
between estrogen and OA is still unclear, a definitive conclusion to this subject remains 
to be stated. 
As estrogen is a pregnancy associated hormone and elevated during the process in 
mammals, pregnancy may be related with metabolism of cartilage and OA. The gene 
expression of normal articular cartilage can be influenced by pregnancy. Gene expression 
of type II collagen, biglycan, collagenase, TIMP-1, IL-1β, TNF-α, TGF-β, iNOS and 
COX-2 has been reported to be suppressed in pregnant rabbits Although pregnancy could 
improve the regenerative capacity of some tissues, the relationship between pregnancy 
and OA cartilage has not been explored in vivo.  
Various animal models have been established to mimic human OA and study the 
pathology of the disease, including surgical/physical, chemical and spontaneous models.   
Considering the gestation period of rats of around 20 days, MIA was chosen as the 
method to induce OA due to its rapid effect(Janusz 2001). MIA induces OA through 
restraining glycolysis of the chondrocytes by inhibiting of glyceraldehyde-3-phosphate 
dehydrogenase. It is different from the natural OA process, as inflammatory mediators 
such as interleukin-1β(IL-1β) and tumor necrosis factor (TNF)-α are increasing. It is 
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important to be noted that the animal model cannot represent all aspects of human 
OA(Goldring 2012). As we focused on the morphology of arthritic cartilage, MIA 
induced OA model was chosen as it is efficient and reproducible. We used a low dose 
MIA model to be able to elucidate the changes in the pregnant rat. Using a low dose, 
prevented severe articular damage from taking place but did result in lower PG content. 
In our results, the attenuation of cartilage as detected by EPIC-μCT was higher in 
MIA groups compared to non-MIA groups. This indicated lower PG levels in MIA 
groups, which is a characteristic of OA. However, there was no significant effect of 
pregnancy on attenuation, volume, thickness and GAG content between the pregnant and 
non-pregnant groups.   
In this study, as no significant effects were found, it is difficult to speculate on 
long term effects of pregnancy and OA. One of the reasons for no changes could be due 
to the short gestation period of rats compared to other mammals. It was possible that if an 
animal with longer gestation was analyzed, significant changes could be observed. 
However, with our data we were unable to prove that pregnancy had any effect on OA 
cartilage. Though no changes were observed, EPIC-µCT provided a successful method to 
analyze articular cartilage in the MIA model.  In order to study the comprehensive effect 
of pregnancy on the cartilage, more parameters such as gene expression, protein levels 





B.1 Medial Meniscal Tear Surgery 
Procedure  
1. All personnel should wear scrubs, masks, head caps, and booties to ensure sterile 
environment. 
2. Surgeons and sterile assistants should scrub in. 
3. After scrubbing in, sterile personnel should assemble surgery tables making care to 
ensure a sterile surgical field.  Non-sterile personnel assist in opening packaging.   
4. Position glass bead sterilizer and turn on. 
5. Position the circulating water bed and turn on to pre-warm for surgery.  Cover with a 
sterile drape. 
6. Animal prep can begin when surgeons are adequately close to operating.  Care should 
be taken to minimize the time that animals are anesthetized.   
7. Transfer a properly prepared rat to the surgery table. Insert the rat’s nose into the nose 
cone, and straighten the tail so that it is not in contact with the feet of the animal. 
8. Non-sterile personnel should hold each foot/toes with forceps to allow sterile 
personnel to wrap the feet with ioban.  
9. Cut a hole in a sterile drape and position over the rat such that only the leg and 
surgical site are exposed. 
10. Have sterile assist orient the leg to have the medial joint space facing the surgeon 
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11. Feel for the joint space using either hemostat or fingers. This can be done by flexing 
the knee 
12. Make a skin incision using the scalpel with the joint space as the mid-point 
13. Perform blunt dissection to reach the MCL 
14. Slide the micro-dissections forceps under the MCL to grip the MCL in the forceps 
teeth (make sure to not cause any trauma with forceps) 
15. Transect the MCL with microdissection scissors (long tip) above the joint space 
16. Peel and cut away tissue attaching MCL to the underlying bone to reveal the 
meniscus 
17. Use cotton swabs to stem the bleeding to observe clearly 
18. Have sterile assist “pop” the knee by bending the knee lightly so as to cause the 
meniscus to separate from the joint 
19. Once, the connection point of meniscus to bone is observed, carefully cut the 
attaching tissue to create space.  
20. Grip the meniscus using the forceps, switch the forceps to the left hand and then use 
the microdissection scissors (short-tip) to transect the meniscus at its narrowest 
21. Check if the meniscus is completely transected using the forceps to hold one of the 
cut ends 






B.2 Intra-articular Injections 
Procedure  
1. Anesthetize the rat and prepare for injection by preparing the rat knee with aseptic 
technique 
2. Prepare solution for injection (26.5 gauge needle on 1ml luer lock syringe) 
3. Use tape cut at .7mm width to stick to the bottom of the needle to ensure that the 
needle is not inserted too deep into the joint space 
4. Have assistant bend the knee with one finger beneath the knee pushing up, so as 
to open the joint space 
5. Feel for the joint space by flexing the knee  
6. Gently insert needle in the selected location through the patella, feeling for any 
barriers 
7. If it hits bone, remove immediately and reposition 
8. If needle is inserted correctly, there will be a little resistance at the beginning 
which will give way indicating needle insertion in the joint space 
9. Once needle is in the joint space, have the assist release the tension in the joint by 
just loosely bending the knee 
10. Gently inject solution and remove the needle slowly. Palpitate the joint to make 
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